<?xml version="1.0" encoding="UTF-8"?><!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Archiving and Interchange DTD v1.1 20151215//EN"  "JATS-archivearticle1.dtd"><article article-type="research-article" dtd-version="1.1" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xmlns:xlink="http://www.w3.org/1999/xlink"><front><journal-meta><journal-id journal-id-type="nlm-ta">elife</journal-id><journal-id journal-id-type="publisher-id">eLife</journal-id><journal-title-group><journal-title>eLife</journal-title></journal-title-group><issn pub-type="epub" publication-format="electronic">2050-084X</issn><publisher><publisher-name>eLife Sciences Publications, Ltd</publisher-name></publisher></journal-meta><article-meta><article-id pub-id-type="publisher-id">66582</article-id><article-id pub-id-type="doi">10.7554/eLife.66582</article-id><article-categories><subj-group subj-group-type="display-channel"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Cell Biology</subject></subj-group><subj-group subj-group-type="heading"><subject>Medicine</subject></subj-group></article-categories><title-group><article-title>The Ca<sup>2+</sup>-activated cation channel TRPM4 is a positive regulator of pressure overload-induced cardiac hypertrophy</article-title></title-group><contrib-group><contrib contrib-type="author" equal-contrib="yes" id="author-223645"><name><surname>Guo</surname><given-names>Yang</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con1"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" equal-contrib="yes" id="author-223646"><name><surname>Yu</surname><given-names>Ze-Yan</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="equal-contrib1">†</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con2"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223647"><name><surname>Wu</surname><given-names>Jianxin</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con3"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223648"><name><surname>Gong</surname><given-names>Hutao</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="fn" rid="con4"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223649"><name><surname>Kesteven</surname><given-names>Scott</given-names></name><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con5"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223650"><name><surname>Iismaa</surname><given-names>Siiri E</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con6"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223651"><name><surname>Chan</surname><given-names>Andrea Y</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con7"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223652"><name><surname>Holman</surname><given-names>Sara</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="fn" rid="con8"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223653"><name><surname>Pinto</surname><given-names>Silvia</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con9"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223654"><name><surname>Pironet</surname><given-names>Andy</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con10"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-46322"><name><surname>Cox</surname><given-names>Charles D</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund5"/><xref ref-type="fn" rid="con11"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223655"><name><surname>Graham</surname><given-names>Robert M</given-names></name><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="fn" rid="con12"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" id="author-223656"><name><surname>Vennekens</surname><given-names>Rudi</given-names></name><xref ref-type="aff" rid="aff4">4</xref><xref ref-type="aff" rid="aff5">5</xref><xref ref-type="other" rid="fund3"/><xref ref-type="other" rid="fund4"/><xref ref-type="fn" rid="con13"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-223657"><name><surname>Feneley</surname><given-names>Michael P</given-names></name><email>michael.feneley@svha.org.au</email><xref ref-type="aff" rid="aff2">2</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="aff" rid="aff6">6</xref><xref ref-type="other" rid="fund1"/><xref ref-type="fn" rid="con14"/><xref ref-type="fn" rid="conf1"/></contrib><contrib contrib-type="author" corresp="yes" id="author-8941"><name><surname>Martinac</surname><given-names>Boris</given-names></name><contrib-id authenticated="true" contrib-id-type="orcid">https://orcid.org/0000-0001-8422-7082</contrib-id><email>b.martinac@victorchang.edu.au</email><xref ref-type="aff" rid="aff1">1</xref><xref ref-type="aff" rid="aff3">3</xref><xref ref-type="other" rid="fund1"/><xref ref-type="other" rid="fund2"/><xref ref-type="fn" rid="con15"/><xref ref-type="fn" rid="conf1"/></contrib><aff id="aff1"><label>1</label><institution>Molecular Cardiology and Biophysics Division, Victor Chang Cardiac Research Institute</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff2"><label>2</label><institution>Cardiac Physiology and Transplantation Division, Victor Chang Cardiac Research Institute</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff3"><label>3</label><institution>St Vincent’s Clinical School, Faculty of Medicine, University of New South Wales</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff><aff id="aff4"><label>4</label><institution>Laboratory of Ion Channel Research, Department of Molecular and Cellular Medicine, Katholieke Universiteit Leuven</institution><addr-line><named-content content-type="city">Leuven</named-content></addr-line><country>Belgium</country></aff><aff id="aff5"><label>5</label><institution>TRP Research Platform Leuven (TRPLe), Katholieke Universiteit Leuven</institution><addr-line><named-content content-type="city">Leuven</named-content></addr-line><country>Belgium</country></aff><aff id="aff6"><label>6</label><institution>Department of Cardiology, St Vincent’s Hospital</institution><addr-line><named-content content-type="city">Sydney</named-content></addr-line><country>Australia</country></aff></contrib-group><contrib-group content-type="section"><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib><contrib contrib-type="senior_editor"><name><surname>Barton</surname><given-names>Matthias</given-names></name><role>Senior Editor</role><aff><institution>University of Zurich</institution><country>Switzerland</country></aff></contrib></contrib-group><author-notes><fn fn-type="con" id="equal-contrib1"><label>†</label><p>These authors contributed equally to this work</p></fn></author-notes><pub-date date-type="publication" publication-format="electronic"><day>30</day><month>06</month><year>2021</year></pub-date><pub-date pub-type="collection"><year>2021</year></pub-date><volume>10</volume><elocation-id>e66582</elocation-id><history><date date-type="received" iso-8601-date="2021-01-15"><day>15</day><month>01</month><year>2021</year></date><date date-type="accepted" iso-8601-date="2021-06-20"><day>20</day><month>06</month><year>2021</year></date></history><permissions><copyright-statement>© 2021, Guo et al</copyright-statement><copyright-year>2021</copyright-year><copyright-holder>Guo et al</copyright-holder><ali:free_to_read/><license xlink:href="http://creativecommons.org/licenses/by/4.0/"><ali:license_ref>http://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This article is distributed under the terms of the <ext-link ext-link-type="uri" xlink:href="http://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License</ext-link>, which permits unrestricted use and redistribution provided that the original author and source are credited.</license-p></license></permissions><self-uri content-type="pdf" xlink:href="elife-66582-v1.pdf"/><abstract><p>Pathological left ventricular hypertrophy (LVH) occurs in response to pressure overload and remains the single most important clinical predictor of cardiac mortality. The molecular pathways in the induction of pressure overload LVH are potential targets for therapeutic intervention. Current treatments aim to remove the pressure overload stimulus for LVH, but do not completely reverse adverse cardiac remodelling. Although numerous molecular signalling steps in the induction of LVH have been identified, the initial step by which mechanical stretch associated with cardiac pressure overload is converted into a chemical signal that initiates hypertrophic signalling remains unresolved. In this study, we show that selective deletion of transient receptor potential melastatin 4 (TRPM4) channels in mouse cardiomyocytes results in an approximately 50% reduction in the LVH induced by transverse aortic constriction. Our results suggest that TRPM4 channel is an important component of the mechanosensory signalling pathway that induces LVH in response to pressure overload and represents a potential novel therapeutic target for the prevention of pathological LVH.</p></abstract><kwd-group kwd-group-type="author-keywords"><kwd>mechanosensitive channels</kwd><kwd>left ventricular hypertrophy</kwd><kwd>cardiovascular disease</kwd><kwd>Ca2+/calmodulin-dependent protein kinase II</kwd></kwd-group><kwd-group kwd-group-type="research-organism"><title>Research organism</title><kwd>Mouse</kwd></kwd-group><funding-group><award-group id="fund1"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>APP1108013</award-id><principal-award-recipient><name><surname>Guo</surname><given-names>Yang</given-names></name><name><surname>Yu</surname><given-names>Ze-Yan</given-names></name><name><surname>Cox</surname><given-names>Charles D</given-names></name><name><surname>Feneley</surname><given-names>Michael P</given-names></name><name><surname>Martinac</surname><given-names>Boris</given-names></name></principal-award-recipient></award-group><award-group id="fund2"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100000925</institution-id><institution>National Health and Medical Research Council</institution></institution-wrap></funding-source><award-id>APP1135974</award-id><principal-award-recipient><name><surname>Martinac</surname><given-names>Boris</given-names></name></principal-award-recipient></award-group><award-group id="fund3"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100003130</institution-id><institution>Fonds Wetenschappelijk Onderzoek</institution></institution-wrap></funding-source><award-id>G0E0317N</award-id><principal-award-recipient><name><surname>Pinto</surname><given-names>Silvia</given-names></name><name><surname>Pironet</surname><given-names>Andy</given-names></name><name><surname>Vennekens</surname><given-names>Rudi</given-names></name></principal-award-recipient></award-group><award-group id="fund4"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100004040</institution-id><institution>KU Leuven</institution></institution-wrap></funding-source><award-id>TRPLe</award-id><principal-award-recipient><name><surname>Pinto</surname><given-names>Silvia</given-names></name><name><surname>Pironet</surname><given-names>Andy</given-names></name><name><surname>Vennekens</surname><given-names>Rudi</given-names></name></principal-award-recipient></award-group><award-group id="fund5"><funding-source><institution-wrap><institution-id institution-id-type="FundRef">http://dx.doi.org/10.13039/501100009287</institution-id><institution>NSW Health</institution></institution-wrap></funding-source><award-id>EMCRFellowship</award-id><principal-award-recipient><name><surname>Cox</surname><given-names>Charles D</given-names></name></principal-award-recipient></award-group><funding-statement>The funders had no role in study design, data collection and interpretation, or the decision to submit the work for publication.</funding-statement></funding-group><custom-meta-group><custom-meta specific-use="meta-only"><meta-name>Author impact statement</meta-name><meta-value>The TRPM4 ion channel has been identified as an important component in the causation of mechanical pressure overload-induced pathological left ventricular hypertrophy, which is a powerful predictor of cardiovascular mortality.</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec id="s1" sec-type="intro"><title id="head_1">Introduction</title><p>Pathological left ventricular hypertrophy (LVH) is the most powerful independent predictor for cardiovascular mortality (<xref ref-type="bibr" rid="bib33">Levy et al., 1990</xref>; <xref ref-type="bibr" rid="bib44">Mudd and Kass, 2008</xref>). It occurs in response to two very common clinical conditions: systemic hypertension and aortic valve stenosis. It manifests as increased cardiomyocyte volume and weight (<xref ref-type="bibr" rid="bib17">Frey et al., 2004</xref>; <xref ref-type="bibr" rid="bib46">Nicks et al., 2020</xref>; <xref ref-type="bibr" rid="bib57">Swynghedauw, 1999</xref>; <xref ref-type="bibr" rid="bib65">Wilde and Brugada, 2011</xref>), which results in increased heart mass, particularly left ventricular (LV) mass. Although pathological LVH commonly occurs as a response to increased cardiac wall stress, sometimes termed ‘compensatory hypertrophy’, it is now well established that the effects of pathological LVH are deleterious for heart function, leading to increased cardiac failure and death (<xref ref-type="bibr" rid="bib33">Levy et al., 1990</xref>; <xref ref-type="bibr" rid="bib44">Mudd and Kass, 2008</xref>). So far, the only treatment for this condition is lowering elevated blood pressure or replacing a stenotic aortic valve. However, these treatments cannot completely reverse the pathological effects on the myocardium once LVH is established. Consequently, understanding the molecular mechanisms underlying pathological LVH may lead to therapies directed at preventing, inhibiting, or reversing pathological LVH and reducing its associated morbidity and mortality.</p><p>The development of pathological LVH depends on upstream stimuli, such as mechanical forces (e.g. pressure overload) or neuroendocrine hormones (e.g. angiotensin II), and distinct downstream signalling mechanisms (<xref ref-type="bibr" rid="bib37">Maillet et al., 2013</xref>; <xref ref-type="bibr" rid="bib45">Nakamura and Sadoshima, 2018</xref>; <xref ref-type="bibr" rid="bib55">Saucerman et al., 2019</xref>; <xref ref-type="bibr" rid="bib59">Tham et al., 2015</xref>; <xref ref-type="bibr" rid="bib60">van Berlo et al., 2013</xref>). Importantly, a large body of work implicates intracellular Ca<sup>2+</sup> levels and subsequent activation of Ca<sup>2+</sup>/calmodulin (CaM)-dependent signalling pathways, such as the calcineurin-nuclear factor of activated T-cells (NFAT)-GATA4 axis, in the induction of pathological LVH (<xref ref-type="bibr" rid="bib5">Bers, 2008</xref>; <xref ref-type="bibr" rid="bib28">Kehat and Molkentin, 2010</xref>; <xref ref-type="bibr" rid="bib42">Molkentin, 2000</xref>; <xref ref-type="bibr" rid="bib43">Molkentin, 2013</xref>; <xref ref-type="bibr" rid="bib41">Molkentin et al., 1998</xref>; <xref ref-type="bibr" rid="bib66">Wilkins et al., 2004</xref>; <xref ref-type="bibr" rid="bib67">Wilkins and Molkentin, 2004</xref>; <xref ref-type="bibr" rid="bib71">Zarain-Herzberg et al., 2011</xref>). Gq-coupled receptors are thought to play an important role in the induction of pathological LVH in response to both neurohumoral stimulation (<xref ref-type="bibr" rid="bib2">Adams et al., 1998</xref>; <xref ref-type="bibr" rid="bib45">Nakamura and Sadoshima, 2018</xref>; <xref ref-type="bibr" rid="bib50">Paradis et al., 2000</xref>) and mechanical forces, such as the increase in LV afterload induced by experimental aortic constriction (<xref ref-type="bibr" rid="bib29">Keys et al., 2002</xref>). Once activated, Gq-coupled receptors are thought to then activate the calcineurin-NFAT pathway (<xref ref-type="bibr" rid="bib28">Kehat and Molkentin, 2010</xref>; <xref ref-type="bibr" rid="bib42">Molkentin, 2000</xref>; <xref ref-type="bibr" rid="bib43">Molkentin, 2013</xref>; <xref ref-type="bibr" rid="bib41">Molkentin et al., 1998</xref>; <xref ref-type="bibr" rid="bib66">Wilkins et al., 2004</xref>; <xref ref-type="bibr" rid="bib67">Wilkins and Molkentin, 2004</xref>).</p><p>Our previous experimental work, however, has demonstrated that although Gq-coupled receptors and the calcineurin-NFAT pathway are essential for the induction of LVH in response to angiotensin II, neither are required for the induction of LVH in response to transverse aortic constriction (TAC), the most common experimental model of LV pressure overload (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>), and one not associated with activation of the renin–angiotensin system (<xref ref-type="bibr" rid="bib72">Zou et al., 2004</xref>). In contrast to the lack of activation of the calcineurin-NFAT pathway with TAC, an alternative Ca<sup>2+</sup>/CaM-dependent signalling pathway, the Ca<sup>2+</sup>/CaM-dependent protein kinase II (CaMKII)-histone deacetylase (HDAC)-myocyte enhancer factor 2 (MEF2) pathway (<xref ref-type="bibr" rid="bib4">Backs et al., 2009</xref>; <xref ref-type="bibr" rid="bib3">Backs et al., 2006</xref>; <xref ref-type="bibr" rid="bib51">Passier et al., 2000</xref>), is activated in response to TAC (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>).</p><p>Left unexplained by our previous work, however, is the mechanism by which the CaMKII-HDAC-MEF2 pathway is activated by TAC, given that this activation is not dependent on Gq-coupled receptors. Prime candidates for mediating this mechanism are mechanosensitive ion channels. In cardiac mechanotransduction, where mechanical stimuli are converted into electrical or chemical signals (<xref ref-type="bibr" rid="bib38">Martinac and Cox, 2017</xref>; <xref ref-type="bibr" rid="bib52">Peyronnet et al., 2016</xref>), Ca<sup>2+</sup>-dependent ion channels, such as transient receptor potential (TRP) channels, act as important modulators of intracellular Ca<sup>2+</sup> homeostasis (<xref ref-type="bibr" rid="bib62">Wang et al., 2018</xref>) and are thought to be unique biosensors that activate specific pathological LVH signalling pathways (<xref ref-type="bibr" rid="bib14">Eder and Molkentin, 2011</xref>; <xref ref-type="bibr" rid="bib69">Wu et al., 2010</xref>). As a Ca<sup>2+</sup>- and voltage-activated non-selective monovalent cation channel, TRP cation channel subfamily melastatin 4 (TRPM4) may contribute to an increase in intracellular Ca<sup>2+</sup> concentration by causing membrane depolarisation (<xref ref-type="bibr" rid="bib32">Launay et al., 2002</xref>), although we and others (<xref ref-type="bibr" rid="bib8">Constantine et al., 2016</xref>; <xref ref-type="bibr" rid="bib19">Gottlieb et al., 2008</xref>; <xref ref-type="bibr" rid="bib47">Nikolaev et al., 2019</xref>) have demonstrated that mammalian TRP channels, including TRPM4, are not directly activated by membrane stretch. Consequently, if TRPM4 plays a role in TAC-induced LVH, it acts as an amplifier of the primary Ca<sup>2+</sup> or voltage signal from a yet to be determined mechanosensitive ion channel or channels. TRPM4 has been functionally characterised in atrial and ventricular cardiomyocytes, both human and rodent (<xref ref-type="bibr" rid="bib21">Guinamard et al., 2004</xref>; <xref ref-type="bibr" rid="bib22">Guinamard et al., 2006</xref>; <xref ref-type="bibr" rid="bib63">Watanabe et al., 2008</xref>). Other studies indicate that TRPM4 contributes to both cardiac function and disease development, including cardiac hypertrophy and heart failure (<xref ref-type="bibr" rid="bib16">Frede et al., 2020</xref>; <xref ref-type="bibr" rid="bib20">Gueffier et al., 2017</xref>; <xref ref-type="bibr" rid="bib24">Hedon et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Jacobs et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Mathar et al., 2014</xref>). Previous studies using <italic>Trpm4</italic> cardiomyocyte-specific knock-out (<italic>Trpm4</italic> cKO) mice have shown that TRPM4 is a negative regulator of angiotensin II-induced cardiac hypertrophy in mice, which involves the calcineurin-NFAT pathway (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>), and that TRPM4 is essential for survival after myocardial infarction (<xref ref-type="bibr" rid="bib24">Hedon et al., 2021</xref>; <xref ref-type="bibr" rid="bib26">Jacobs et al., 2015</xref>). However, whether TRPM4 plays a role in mechanical pressure overload-induced LVH has yet to be determined.</p><p>Here, we investigate the role of TRPM4 in pressure overload LVH induced by TAC in homozygous <italic>Trpm4</italic> cKO mice (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>) as compared to wild-type (WT) control mice. We demonstrate that loss of cardiomyocyte TRPM4 significantly attenuates the development of LVH observed in response to TAC in WT mice. Moreover, this effect is associated with reduced activation of the CaMKII-HDAC4-MEF2 pathway.</p></sec><sec id="s2" sec-type="results"><title id="head_2">Results</title><sec id="s2-1"><title id="head_3">Development of LV hypertrophy in response to pressure overload at 14 days after TAC in WT mice</title><p>As documented in our previous study (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>), TAC-induced cardiac hypertrophy is a response to LV pressure overload. As expected, LV systolic pressure increased by ~65 mmHg (p&lt;0.001) 14 days after TAC (<xref ref-type="table" rid="table1">Table 1</xref>), whereas heart rate (<xref ref-type="table" rid="table1">Table 1</xref>), dP/dt<sub>max</sub>, and dP/dt<sub>min</sub> (<xref ref-type="table" rid="table1">Table 1</xref>) remained unaltered. Consistent with 14 days of TAC resulting in a compensated LVH model, body weight (BW) and lung weight (LW) (<xref ref-type="table" rid="table1">Table 1</xref>) remained unchanged in TAC mice compared to sham-operated mice. These results indicate that our TAC model at 14 days remains an excellent model of compensated LVH rather than heart failure.</p><table-wrap id="table1" position="float"><label>Table 1.</label><caption><title>Haemodynamic parameters were measured in wild-type (WT) mice 14 days after subjected to TAC versus sham-operated controls (n = 7–11/group).</title><p>Post-mortem analysis of mice 2 days or 14 days after sham or TAC; LVH developed 14 days after TAC, indicated by the ratios of HW/BW, LVW/BW, and LVW/TL in WT mice subjected to TAC versus sham-operated controls. Cardiac fibrosis was evaluated by Masson’s trichrome staining of LV tissue from WT mice subjected to 2 days or 14 days of TAC versus sham-operated controls; cardiac fibrosis areas were graded (n = 5–6/group). Relative Collagen III (Col3a1) mRNA expression was normalised by GAPDH and calculated as fold change relative to sham in 2 days and 14 days groups, respectively (n = 4/group). LVSP: left ventricular systolic pressure; HR: heart rate; dP/dt: first derivative of pressure with respect to time. BW: body weight; HW: heart weight; LVW: left ventricular weight; LW: lung weight; TL: tibia length; HW/BW: heart weight to body weight ratio; LVW/BW: LV weight to body weight ratio; LVW/TL: LV weight to tibia length ratio; LW/BW: lung weight to body weight ratio. Results are presented as means ± SEM. **p&lt;0.01, ***p&lt;0.001, compared between sham- and TAC-operated groups.</p><p><supplementary-material id="table1sdata1"><label>Table 1—source data 1.</label><caption><title>Haemodynamic and anatomical parameters.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-table1-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">2 days</th><th colspan="2">14 days</th></tr><tr><th>Sham</th><th>TAC</th><th>Sham</th><th>TAC</th></tr></thead><tbody><tr><td>Haemodynamic parameter</td><td colspan="4"/></tr><tr><td>n</td><td colspan="2" rowspan="7"/><td>7</td><td>7</td></tr><tr><td>HR (bpm)</td><td>506 ± 4</td><td>506 ± 3</td></tr><tr><td>Aortic systolic pressure (mmHg)</td><td>103 ± 1</td><td>164 ± 2***</td></tr><tr><td>Aortic diastolic pressure (mmHg)</td><td>76 ± 1</td><td>74 ± 1</td></tr><tr><td>LV systolic <break/>Pressure (mmHg)</td><td>105 ± 3</td><td>164 ± 8***</td></tr><tr><td>dP/dt<sub>max</sub> (mmHg/s)</td><td>9438 ± 367</td><td>9838 ± 259</td></tr><tr><td>dP/dt<sub>min</sub> (mmHg/s)</td><td>−9666 ± 377</td><td>−10108 ± 364</td></tr><tr><td>Anatomical parameter</td><td colspan="4"/></tr><tr><td>n</td><td>8</td><td>8</td><td>11</td><td>11</td></tr><tr><td>BW (g)</td><td>28.5 ± 0.3</td><td>27.7 ± 0.5</td><td>28.6 ± 0.3</td><td>27.2 ± 0.5</td></tr><tr><td>HW (mg)</td><td>136.7 ± 2.2</td><td>132.8 ± 1.3</td><td>133.1 ± 1.9</td><td>176.1 ± 3.6 ***</td></tr><tr><td>LVW (mg)</td><td>98.0 ± 2.0</td><td>97.7 ± 1.4</td><td>96.4 ± 1.8</td><td>136.1 ± 1.4 ***</td></tr><tr><td>LW (mg)</td><td>141.9 ± 0.9</td><td>143.6 ± 1.5</td><td>146.9 ± 1.8</td><td>147.0 ± 1.9</td></tr><tr><td>TL (mm)</td><td>17.4 ± 0.1</td><td>17.5 ± 0.2</td><td>17.5 ± 0.2</td><td>17.2 ± 0.1</td></tr><tr><td>HW/BW (mg/g)</td><td>4.8 ± 0.1</td><td>4.8 ± 0.1</td><td>4.6 ± 0.1</td><td>6.6 ± 0.1 ***</td></tr><tr><td>LVW/BW (mg/g)</td><td>3.4 ± 0.1</td><td>3.5 ± 0.1</td><td>3.4 ± 0.1</td><td>5.1 ± 0.1 ***</td></tr><tr><td>LVW/TL (mg/mm)</td><td>5.6 ± 0.1</td><td>5.6 ± 0.1</td><td>5.3 ± 0.1</td><td>7.9 ± 0.1 ***</td></tr><tr><td>LW/BW (mg/g)</td><td>5.0 ± 0.1</td><td>5.2 ± 0.1</td><td>5.2 ± 0.1</td><td>5.4 ± 0.1</td></tr><tr><th colspan="5">Assessment of cardiac fibrosis</th></tr><tr><td>n</td><td>5</td><td>5</td><td>6</td><td>6</td></tr><tr><td>Fibrosis areas (%)</td><td>4.0 ± 0.2</td><td>3.6 ± 0.2</td><td>4.4 ± 0.1</td><td>12.4 ± 0.5***</td></tr><tr><td>n</td><td>4</td><td>4</td><td>4</td><td>4</td></tr><tr><td>Collagen III mRNA expression <break/>(fold change)</td><td>1.0 ± 0.1</td><td>5.7 ± 0.8**</td><td>1.0 ± 0.1</td><td>5.1 ± 0.7**</td></tr></tbody></table></table-wrap><p>Representative photos illustrate the size differences of WT mouse hearts after 2 days and 14 days of sham or TAC (<xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>). LVH was not detected 2 days after TAC (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), whereas we observed significant LVH in WT mice 14 days after TAC, as evidenced by increases in heart weight (HW, p&lt;0.001), left ventricular weight (LVW, p&lt;0.001), and the ratios of heart weight/body weight (HW/BW, p&lt;0.001), left ventricle weight/body weight (LVW/BW, p&lt;0.001), and left ventricle weight/tibial length (LVW/TL, p&lt;0.001), without changes in BW or TL, when compared with the sham-operated animals (<xref ref-type="table" rid="table1">Table 1</xref>). Consistent with the development of pathological hypertrophy, TAC was associated with an increase in cardiac fibrosis (p&lt;0.001, <xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1B</xref>) and enhanced collagen III (<italic>Col3a1</italic>) expression (p&lt;0.001, <xref ref-type="table" rid="table1">Table 1</xref>).</p><p>Haemodynamic parameters were measured in wild-type (WT) mice 14 days after being subjected to TAC versus sham-operated controls (n = 7–11/group). Post-mortem analysis of mice 2 days or 14 days after sham or TAC; LVH developed 14 days after TAC, indicated by the ratios of HW/BW, LVW/BW, and LVW/TL in WT mice subjected to TAC versus sham-operated controls. Cardiac fibrosis was evaluated by Masson’s trichrome staining of LV tissue from WT mice subjected to 2 days or 14 days of TAC versus sham-operated controls; cardiac fibrosis areas were graded (n = 5–6/group). Relative Collagen III (<italic>Col3a1</italic>) mRNA expression was normalised by GAPDH and calculated as fold change relative to sham in 2 days and 14 days groups, respectively (n = 4/group). LVSP: left ventricular systolic pressure; HR: heart rate; dP/dt: first derivative of pressure with respect to time; BW: body weight; HW: heart weight; LVW: left ventricular weight; LW: lung weight; TL: tibia length; HW/BW: heart weight to body weight ratio; LVW/BW: LV weight to body weight ratio; LVW/TL: LV weight to tibia length ratio; LW/BW: lung weight to body weight ratio. Results are presented as means ± SEM. **p&lt;0.01, ***p&lt;0.001, compared between sham- and TAC-operated groups.</p></sec><sec id="s2-2"><title id="head_4">Early gene markers of induction of pathological hypertrophy in WT mice</title><p>Although there was no significant LVH 2 days after TAC (<xref ref-type="table" rid="table1">Table 1</xref>, <xref ref-type="fig" rid="fig1s1">Figure 1—figure supplement 1A</xref>), induction of hypertrophy-associated genes (atrial natriuretic peptide [ANP, <italic>Nppa</italic>; 9.9-fold, p&lt;0.01], brain natriuretic peptide [BNP, <italic>Nppb</italic>; 8.1-fold, p&lt;0.01], and α-skeletal actin [α-SA, <italic>Acta1</italic>; 4.5-fold, p&lt;0.01]) was already evident at this time (<xref ref-type="table" rid="table2">Table 2</xref>), and expression of these genes remained high at 14 days (ANP, <italic>Nppa</italic>; p&lt;0.001, BNP, <italic>Nppb</italic>; p&lt;0.001, and α-SA, <italic>Acta1</italic>; p&lt;0.001,<xref ref-type="table" rid="table2">Table 2</xref>).</p><table-wrap id="table2" position="float"><label>Table 2.</label><caption><title>Early markers of LVH induction in response to left ventricular pressure overload in WT mice.</title><p>Relative mRNA expression of ANP (Nppa), BNP (Nppb), and a-SA (Acta1) after 2 days or 14 days of TAC compared to sham (n = 4–5/group). The relative mRNA expression was normalised by GAPDH and calculated as fold change relative to sham in 2 days and 14 days groups, respectively.Results are presented as means ± SEM. **p&lt;0.01, ***p&lt;0.001, compared between sham- and TAC-operated groups.</p><p><supplementary-material id="table2sdata1"><label>Table 2—source data 1.</label><caption><title>Early gene markers.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-table2-data1-v1.xlsx"/></supplementary-material></p></caption><table frame="hsides" rules="groups"><thead><tr><th rowspan="2"/><th colspan="2">2 days</th><th colspan="2">14 days</th></tr><tr><th>Sham</th><th>TAC</th><th>Sham</th><th>TAC</th></tr></thead><tbody><tr><td>LVH markers (fold change)</td><td colspan="4"/></tr><tr><td>n</td><td>4</td><td>4</td><td>5</td><td>5</td></tr><tr><td>ANP</td><td>1.0 ± 0.1</td><td>9.9 ± 1.1**</td><td>1.0 ± 0.1</td><td>9.6 ± 0.7***</td></tr><tr><td>BNP</td><td>1.0 ± 0.1</td><td>8.1 ± 0.8**</td><td>1.0 ± 0.2</td><td>7.5 ± 0.4***</td></tr><tr><td>α-SA</td><td>1.0 ± 0.1</td><td>4.5 ± 0.5**</td><td>1.0 ± 0.1</td><td>4.2 ± 0.4***</td></tr></tbody></table></table-wrap></sec><sec id="s2-3"><title id="head_5">TRPM4 expression was downregulated in response to LV pressure overload in WT mice</title><p>To examine whether the TRPM4 ion channel is involved in TAC-induced LVH, we conducted real-time quantitative PCR (RT-PCR) on LV tissues or isolated LV cardiomyocytes from TAC- or sham-operated hearts. <italic>Trpm4</italic> mRNA expression in LV tissue (<xref ref-type="fig" rid="fig1">Figure 1A</xref>) and isolated cardiomyocytes (<xref ref-type="fig" rid="fig1">Figure 1B</xref>) fell by 50% (p&lt;0.001) and 57% (p&lt;0.001), respectively, in response to 2 days of TAC, and expression continued to be reduced by 30% (p&lt;0.05, <xref ref-type="fig" rid="fig1">Figure 1A</xref>) and 40% (p&lt;0.001, <xref ref-type="fig" rid="fig1">Figure 1B</xref>), respectively, at 14 days. Consistent with the mRNA changes, TRPM4 protein expression in LV tissue and isolated cardiomyocytes also fell significantly, particularly in cardiomyocytes, after 14 days of TAC (p&lt;0.001) (<xref ref-type="fig" rid="fig1">Figure 1C–E</xref>).</p><fig-group><fig id="fig1" position="float"><label>Figure 1.</label><caption><title>TRPM4 expression was downregulated in response to left ventricular (LV) pressure overload.</title><p>(<bold>A</bold>) Relative mRNA expression of <italic>Trpm4</italic> in LV tissue and (<bold>B</bold>) in LV cardiomyocytes (CMs) after 2 days and 14 days of sham and TAC. (<bold>C</bold>) Representative western blots of TRPM4 protein expression in LV tissue (left panel) and in LV cardiomyocytes (right panel). (<bold>D</bold>) Western blots from LV tissue and (<bold>E</bold>) LV cardiomyocytes after 2 days and 14 days of TAC were quantified for TRPM4 protein expression. Relative TRPM4 mRNA and protein expression in the LV tissue and cardiomyocytes were normalised by GAPDH and calculated as fold change relative to sham in 2 days and 14 days groups, respectively. Results are presented as means ± SEM. *p&lt;0.05, ***p&lt;0.001 vs. sham-operated groups.</p><p><supplementary-material id="fig1sdata1"><label>Figure 1—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig1">Figure 1A,B,D and E</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig1-v1.tif"/></fig><fig id="fig1s1" position="float" specific-use="child-fig"><label>Figure 1—figure supplement 1.</label><caption><title>Enlarged heart and cardiac fibrosis were detected 14 days after TAC.</title><p>(<bold>A</bold>) Representative photos of hearts from WT mice 2 days or 14 days after sham or TAC. (<bold>B</bold>) Representative photos of cardiac fibrosis, evaluated by Masson’s trichrome staining of LV tissue from WT mice subjected to TAC versus sham-operated controls. Scale bar = 100 µm.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig1-figsupp1-v1.tif"/></fig></fig-group></sec><sec id="s2-4"><title id="head_6">TRPM4 deficiency decreases the hypertrophic response to TAC-induced pressure overload</title><p>To further investigate the role of TRPM4 channels in pressure overload-induced LVH, we performed TAC or sham surgery in mice with cardiomyocyte-specific, conditional deletion of <italic>Trpm4</italic> (<italic>Trpm4</italic> cKO) using Cre expression driven by the <italic>Myl7</italic> promoter (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>). Results obtained in these <italic>Trpm4</italic> cKO mice were compared with those in WT (<italic>Trpm4<sup>+/+</sup></italic>) mice. Haemodynamic and anatomical parameters obtained after 2 days and 14 days of sham/TAC in WT and <italic>Trpm4</italic> cKO mice are shown in <xref ref-type="supplementary-material" rid="supp1">Supplementary file 1</xref>. TAC produced a similar degree of LV pressure overload in both WT (p&lt;0.001) and <italic>Trpm4</italic> cKO (p&lt;0.001) mice when compared with sham-operated groups (<xref ref-type="fig" rid="fig2">Figure 2A</xref>) but did not alter heart rate (<xref ref-type="fig" rid="fig2">Figure 2B</xref>), cardiac contractility (<xref ref-type="fig" rid="fig2">Figure 2C,D</xref>), LW (<xref ref-type="fig" rid="fig2">Figure 2E</xref>), or BW (<xref ref-type="fig" rid="fig2">Figure 2G</xref>). <xref ref-type="fig" rid="fig2">Figure 2F</xref> illustrates representative images of WT and <italic>Trpm4</italic> cKO mouse hearts after 14 days of sham or TAC. No LVH was detected 2 days after TAC in either <italic>Trpm4</italic> cKO mice or WT mice when compared with sham-operated groups (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>). After 14 days, TAC induced a 32, 42, and 44% increase (all p&lt;0.001) in HW/BW ratio, LVW/BW ratio, and LVW/TL ratio, respectively, in WT mice when compared with sham-operated controls (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>). However, this hypertrophic response to 14 days of TAC was attenuated in <italic>Trpm4</italic> cKO mice, as evident by only a 17, 20, and 23% increase (all p&lt;0.001) in HW/BW ratio, LVW/BW ratio, and LVW/TL ratio, respectively (<xref ref-type="fig" rid="fig2">Figure 2H–J</xref>). These findings demonstrate that when compared with WT mice, <italic>Trpm4</italic> cKO mice developed approximately 50% less LVH (p&lt;0.001) in response to TAC.</p><fig id="fig2" position="float"><label>Figure 2.</label><caption><title>The hypertrophic response of WT and <italic>Trpm4</italic> cKO mice to TAC-induced LV pressure overload.</title><p>(<bold>A</bold>) Systolic pressure, (<bold>B</bold>) heart rate, (<bold>C, D</bold>) dP/dt after 14 days of sham or TAC in WT and <italic>Trpm4</italic> cKO mice. (n = 6–7/group). (<bold>E</bold>) Lung weight after 14 days of sham or TAC in WT and <italic>Trpm4</italic> cKO mice. (n = 7–9/group). (<bold>F</bold>) Representative photos indicate heart size differences after 14 days of sham or TAC in WT and <italic>Trpm4</italic> cKO mice. (<bold>G</bold>) Body weight, (<bold>H</bold>) Heart weight, and (<bold>I, J</bold>) LV weight normalised to body weight and tibia length, in WT and <italic>Trpm4</italic> cKO mice after 2 days and 14 days of sham or TAC. (n = 7–9/group). (<bold>K</bold>) Representative micrographs and (<bold>L</bold>) quantitation of Masson’s trichrome staining of LV tissue from WT mice and <italic>Trpm4</italic> cKO mice after 14 days of sham or TAC (n = 3/group), scale bar = 200 µm in (<bold>K</bold>). (<bold>M</bold>) Relative collagen III (<italic>Col3a1</italic>) mRNA expression after 14 days of sham or TAC. (n = 6/group). The mRNA relative expression was normalised by comparison to GAPDH and calculated as fold change relative to sham in WT and <italic>Trpm4</italic> cKO groups, respectively. Results are presented as means ± SEM. *p&lt;0.05, ***p&lt;0.001.</p><p><supplementary-material id="fig2sdata1"><label>Figure 2—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig2">Figure 2A,B,C,D,E,G,H,I,J,L, and M</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig2-v1.tif"/></fig></sec><sec id="s2-5"><title id="head_7">Reduced fibrosis in <italic>Trpm4</italic> cKO hearts after TAC</title><p>We evaluated cardiac fibrosis in response to pressure overload in <italic>Trpm4</italic> cKO hearts and WT hearts by Masson’s trichrome staining (<xref ref-type="fig" rid="fig2">Figure 2K</xref>). When compared with an average 3.17-fold increase (p&lt;0.001) in cardiac fibrosis in WT TAC hearts, the increase in <italic>Trpm4</italic> cKO TAC hearts was only 1.75-fold (p&lt;0.05) (<xref ref-type="fig" rid="fig2">Figure 2L</xref>). In addition, we found a significant increase in collagen III (<italic>Col3a1</italic>) mRNA expression in WT TAC hearts when compared with WT sham hearts (p&lt;0.001). However, there was no significant increase in collagen III (<italic>Col3a1</italic>) mRNA expression in <italic>Trpm4</italic> cKO TAC hearts when compared with sham hearts (<xref ref-type="fig" rid="fig2">Figure 2M</xref>). Thus, <italic>Trpm4</italic> inactivation attenuated the fibrotic response to TAC.</p></sec><sec id="s2-6"><title id="head_8">TRPM4 deficiency reduced the expression of hypertrophy markers in response to TAC-induced pressure overload</title><p>Consistent with the development of pathological hypertrophy, both 2 and 14 days of TAC in WT mice significantly enhanced expression of the hypertrophy-associated genes, ANP (<italic>Nppa</italic>), BNP (<italic>Nppb</italic>), and α-SA (<italic>Acta1</italic>) (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>). However, these gene markers remained unchanged with TAC in <italic>Trpm4</italic> cKO mice (<xref ref-type="fig" rid="fig3">Figure 3A,B</xref>), except for ANP (<italic>Nppa</italic>) at 14 days. These data indicate that loss of TRPM4 attenuates the activation of hypertrophic marker genes in response to TAC.</p><fig id="fig3" position="float"><label>Figure 3.</label><caption><title>Comparison of gene expression of LVH markers in response to TAC-induced pressure overload in WT and <italic>Trpm4</italic> cKO mice.</title><p>(<bold>A</bold>) Relative mRNA expression of ANP (<italic>Nppa</italic>), BNP (<italic>Nppb</italic>), and α-SA (<italic>Acta1</italic>) after 2 days of TAC compared to sham-operated mice. (n = 6/group). (<bold>B</bold>) Relative mRNA expression of ANP (<italic>Nppa</italic>), BNP (<italic>Nppb</italic>), and α-SA (<italic>Acta1</italic>) after 14 days of sham and TAC. (n = 6/group). The mRNA relative expression was normalised by GAPDH and calculated as fold change relative to WT sham in 2 days and 14 days groups, respectively. Results are presented as means ± SEM, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig3sdata1"><label>Figure 3—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig3">Figure 3A,B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig3-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig3-v1.tif"/></fig></sec><sec id="s2-7"><title id="head_9">CaMKII-HDAC4-MEF2 hypertrophic signalling pathway in WT and <italic>Trpm4</italic> cKO mouse hearts</title><p>We next examined the molecular signalling pathways mediating LVH in both WT and <italic>Trpm4</italic> cKO hearts after 2 days of TAC, a time at which molecular signalling is already activated in response to the increased haemodynamic load induced by TAC (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>), but before measurable LVH has developed.</p><p>The cytoplasmic and the nuclear fractions of LV tissue were separated as described in Materials and methods. High fraction purity was confirmed by western blot using antibodies against marker proteins specific for cytoplasmic (glyceraldehyde 3-phosphate dehydrogenase, GAPDH) and nuclear (Histone H2B) fractions (<xref ref-type="fig" rid="fig4s1">Figure 4—figure supplement 1</xref>).</p><p>Representative images of key cytoplasmic and nuclear proteins detected by western blot analysis are shown in <xref ref-type="fig" rid="fig4">Figure 4A</xref>. Quantitative data for cytoplasmic and nuclear proteins, normalised by GAPDH and Histone H2B, respectively, are shown in <xref ref-type="fig" rid="fig4">Figure 4B</xref>. We first investigated whether CaMKIIδ activity is increased in response to pressure overload by measuring both total CaMKIIδ expression and auto-phosphorylated CaMKII (p-CaMKII) at threonine 287 (Thr287), a marker of CaMKII activation (<xref ref-type="bibr" rid="bib31">Lai et al., 1987</xref>; <xref ref-type="bibr" rid="bib35">Luczak et al., 2020</xref>). We found that in WT hearts, 2 days of TAC resulted in a significant increase in the total CaMKIIδ protein level in cytoplasmic (p&lt;0.01) and nuclear fractions (p&lt;0.01), accompanied by increased p-CaMKII protein levels in both the cytoplasm (p&lt;0.05) and nucleus (p&lt;0.01). Associated with this increase, there was a rise in total cytoplasmic HDAC4 (p&lt;0.01) and phosphorylated HDAC4 (p-HDAC4) levels (p<italic>&lt;</italic>0.001), but no change in nuclear HDAC4. This 2.11-fold increase in the cytoplasmic/nuclear ratio of HDAC4 (p&lt;0.01) in WT hearts indicates that TAC-induced pressure overload leads to the nuclear export of HDAC4 in WT TAC hearts. This increase was accompanied by a 1.76-fold increase of MEF2A levels in the nucleus (p&lt;0.05), which together with the de-repression of MEF2A activity would account for the induction of LVH.</p><fig-group><fig id="fig4" position="float"><label>Figure 4.</label><caption><title>CaMKII-HDAC4-MEF2 signalling pathway in response to TAC after 2 days in WT and <italic>Trpm4</italic> cKO mouse hearts.</title><p>(<bold>A</bold>) Representative western blots showing the expression of key proteins in the CaMKII-HDAC4-MEF2 signalling pathway in the cytoplasm (left) and nucleus (right). (<bold>B</bold>) Cytoplasmic (left) and nuclear (right) quantitative data were normalised by GAPDH and Histone H2B, respectively. Fold changes and cytoplasmic/nuclear ratios were calculated relative to sham groups, in each genotype. Results are presented as means ± SEM, n = 6/group, *p&lt;0.05, **p&lt;0.01, ***p&lt;0.001.</p><p><supplementary-material id="fig4sdata1"><label>Figure 4—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig4">Figure 4B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig4-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig4-v1.tif"/></fig><fig id="fig4s1" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 1.</label><caption><title>Demonstration of successful fractionation of compartments.</title><p>The purity of the fractions extracted from the LV tissue was assessed by western blot using specific marker proteins: GAPDH for cytoplasmic fraction and histone H2B for nuclear fraction. Each fraction (n = 6/group) was run side-by-side on the same blot and then probed separately against each of two primary antibodies: anti-GAPDH and anti-Histone H2B to validate purity of fraction.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig4-figsupp1-v1.tif"/></fig><fig id="fig4s2" position="float" specific-use="child-fig"><label>Figure 4—figure supplement 2.</label><caption><title>Cytoplasmic/nuclear ratio of the key proteins in CaMKII-HDAC4-MEF2 signalling pathway.</title><p>Cytoplasmic/nuclear ratios are shown as fold changes relative to sham groups, in each genotype. Results are presented as means ± SEM, n = 6/group, *p&lt;0.05, ***p&lt;0.001.</p><p><supplementary-material id="fig4s2sdata1"><label>Figure 4—figure supplement 2—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig4-figsupp2-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig4-figsupp2-v1.tif"/></fig></fig-group><p>In contrast to the effects of TAC in WT hearts, in <italic>Trpm4</italic> cKO hearts, TAC produced a decrease in cytoplasmic CaMKIIδ levels (0.66-fold of that observed in sham hearts; p&lt;0.001). Consistent with this, the cytoplasmic p-CaMKII levels in TAC hearts also decreased (0.63-fold of that observed in sham hearts; p&lt;0.01). Although the increase in nuclear CaMKIIδ was similar (p&lt;0.05) to that observed with TAC in WT hearts, the nuclear p-CaMKII levels showed no significant difference between sham and TAC in <italic>Trpm4</italic> cKO hearts, which indicates less nuclear CaMKIIδ activation by TAC in <italic>Trpm4</italic> cKO hearts. We found that p-HDAC4 increased in <italic>Trpm4</italic> cKO TAC hearts in both the cytoplasm (p&lt;0.05) and the nucleus (p&lt;0.05), but there was no change in total HDAC4. Thus, the cytoplasmic/nuclear ratio of HDAC4 remained the same in <italic>Trpm4</italic> cKO TAC hearts as in sham hearts, indicating inhibition of nuclear HDAC4 export in TAC-treated <italic>Trpm4</italic> cKO hearts. In addition, consistent with MEF2A activation driving hypertrophy development, reduced LVH in <italic>Trpm4</italic> cKO TAC hearts was associated with a smaller (1.26-fold) increase in MEF2A levels in the nucleus (p&lt;0.05) when compared with WT TAC hearts. For completeness, the cytoplasmic/nuclear ratios of other relevant proteins in this signalling pathway are shown in <xref ref-type="fig" rid="fig4s2">Figure 4—figure supplement 2</xref>.</p><p>Taken together, these data implicate the CaMKII-HDAC4-MEF2 hypertrophic signalling pathway in mediating TAC-induced LVH, but the extent of the hypertrophic response is regulated by TRPM4 channels.</p></sec><sec id="s2-8"><title id="head_10">Calcineurin-NFAT hypertrophic signalling pathway in WT and <italic>Trpm4</italic> cKO mouse hearts</title><p>Next, we examined the expression of proteins involved in the calcineurin-NFAT hypertrophic signalling pathway. Representative images of key cytoplasmic and nuclear proteins detected by western blot analysis are shown in <xref ref-type="fig" rid="fig5">Figure 5A</xref>. Quantitative data for cytoplasmic and nuclear proteins, normalised by GAPDH and Histone H2B, respectively, are shown in <xref ref-type="fig" rid="fig5">Figure 5B</xref>. In WT hearts, there was no significant difference in cytoplasmic or nuclear NFATc4 protein expression in sham and TAC hearts after 2 days. Consistent with these findings, total GSK3β, serine-9 phosphorylated GSK3β and GATA4 levels were also unchanged in response to TAC. These findings indicate that TAC did not result in increased nuclear translocation of NFATc4, the most reliable indicator of calcineurin activation (<xref ref-type="bibr" rid="bib43">Molkentin, 2013</xref>), and confirm our previous finding (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>) that the calcineurin-NFAT pathway is not activated by TAC.</p><fig-group><fig id="fig5" position="float"><label>Figure 5.</label><caption><title>Calcineurin-NFAT signalling pathway in response to TAC after 2 days in WT and <italic>Trpm4</italic> cKO mouse hearts.</title><p>(<bold>A</bold>) Representative western blots showing the expression of key proteins in the calcineurin-NFAT signalling pathway in cytoplasm (left) and nucleus (right). (<bold>B</bold>) Cytoplasmic (left) and nuclear (right) quantitative data were normalised by GAPDH and Histone H2B, respectively. Fold changes and cytoplasmic/nuclear ratios were calculated relative to sham groups, in each genotype. Results are presented as means ± SEM, n = 5–6/group, *p&lt;0.05, **p&lt;0.01.</p><p><supplementary-material id="fig5sdata1"><label>Figure 5—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig5">Figure 5B</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig5-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig5-v1.tif"/></fig><fig id="fig5s1" position="float" specific-use="child-fig"><label>Figure 5—figure supplement 1.</label><caption><title>Cytoplasmic/nuclear ratio of the key proteins in calcineurin-NFAT signalling pathway.</title><p>Cytoplasmic/nuclear ratios are shown as fold changes relative to sham groups, in each genotype. Results are presented as means ± SEM, n = 6/group.</p><p><supplementary-material id="fig5s1sdata1"><label>Figure 5—figure supplement 1—source data 1.</label><caption><title>Source data file (Excel) for <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</title></caption><media mime-subtype="xlsx" mimetype="application" xlink:href="elife-66582-fig5-figsupp1-data1-v1.xlsx"/></supplementary-material></p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig5-figsupp1-v1.tif"/></fig></fig-group><p>In contrast to WT hearts, a 1.28-fold increase in nuclear NFATc4 (p&lt;0.05) was observed in <italic>Trpm4</italic> cKO hearts after TAC, which led to a 0.31-fold decrease in the cytoplasmic/nuclear ratio compared to sham-operated hearts (p&lt;0.01). This indicated lower nuclear export of NFATc4 in the <italic>Trpm4</italic> cKO TAC hearts when compared to sham hearts. Accordingly, we found a 1.20-fold increase in nuclear p-GSK3β (serine 9, Ser9) (p&lt;0.05) in <italic>Trpm4</italic> cKO TAC hearts. As phosphorylation at the serine 9 residue indicates inactivation of GSK3β, these findings suggest that the GSK3β-mediated export of NFATc4 from the nucleus was partially inhibited, which is consistent with the increased level of NFATc4 in the nucleus. Furthermore, accompanied by the increase in nuclear NFATc4, a 1.18-fold increase in GATA4 expression (p&lt;0.05) in the nucleus was observed in <italic>Trpm4</italic> cKO TAC hearts. All these observations are consistent with a reduction in the tonic inhibition of calcineurin by CaMKII (<xref ref-type="bibr" rid="bib12">De Koninck and Schulman, 1998</xref>; <xref ref-type="bibr" rid="bib30">Kreusser et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">MacDonnell et al., 2009</xref>) in <italic>Trpm4</italic> cKO hearts after TAC. For completeness, the cytoplasmic/nuclear ratios of other relevant proteins in this signalling pathway are shown in <xref ref-type="fig" rid="fig5s1">Figure 5—figure supplement 1</xref>.</p></sec></sec><sec id="s3" sec-type="discussion"><title id="head_11">Discussion</title><p>In the present study, we employed mice subjected to TAC as an in vivo cardiac hypertrophy model to investigate the role of the TRPM4 ion channels in pressure overload-induced pathological LVH. We compared <italic>Trpm4</italic> cKO mice with WT controls. The experimental animals were examined 2 days after surgery when the molecular signalling pathway that drives LVH is switched on in response to the increased haemodynamic load induced by TAC but, importantly, before LVH has developed. In addition, the experimental animals were examined 14 days after surgery when the TAC-induced LVH phenotype is evident.</p><p>First, we found that TRPM4 channel expression in the WT mouse heart was modified by TAC-induced pressure overload hypertrophy. At 2 days and 14 days after TAC, both <italic>Trpm4</italic> mRNA and protein expression were downregulated in LV tissue and isolated cardiomyocytes, suggesting that TRPM4 plays a role in TAC-induced LVH. Second, we demonstrated that the role of TRPM4 was pro-hypertrophic by performing sham and TAC surgery in <italic>Trpm4</italic> cKO mice. This demonstrated that a reduction in TRPM4 expression in cardiomyocytes dampens the hypertrophic response to TAC, as evident by an approximately 50% reduction in the degree of LVH and LV fibrosis in <italic>Trpm4</italic> cKO animals at 14 days after TAC, as compared with WT animals. Finally, to investigate the hypertrophic signalling pathways activated in response to pressure overload, we examined both the CaMKII-HDAC4-MEF2 and calcineurin-NFAT signalling pathways 2 days after TAC in WT and <italic>Trpm4</italic> cKO mice (<xref ref-type="fig" rid="fig6">Figure 6</xref>). This confirmed our previous finding that the CaMKII-HDAC4-MEF2 pathway was activated in response to TAC in WT mice (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>), but also revealed the new finding of reduced activation of the CaMKII-HDAC4-MEF2 pathway after TAC in <italic>Trpm4</italic> cKO animals.</p><fig id="fig6" position="float"><label>Figure 6.</label><caption><title>Schematic of the putative TAC-induced pathway that culminates in left ventricular hypertrophy.</title><p>A Ca<sup>2+</sup>-permeable MS channel (e.g. Piezo1, TRPV2, TRPV4) acts as the mechanotransducer providing local Ca<sup>2+</sup> that in turn stimulates TRPM4. The Na<sup>+</sup>-permeable TRPM4 activity then could either stimulate voltage-gated Ca<sup>2+</sup> channels through membrane depolarisation or induce reverse activity of the Na<sup>+</sup>/ Ca<sup>2+</sup>exchanger through local Na<sup>+</sup> loading. Either of these outcomes would lead to a high-amplitude increase in local Ca<sup>2+</sup>. Calmodulin then responds to this high-amplitude Ca<sup>2+</sup> stimulus through the lower affinity Ca<sup>2+</sup> binding site at its N-lobe which subsequently activates CaMKIIδ and thus stimulates the CaMKII-HDAC4-MEF2 pathway as shown in <xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>. Calcineurin activation is inhibited by the activated CaMKIIδ and is activated preferentially by low-amplitude Ca<sup>2+</sup> signalling via Gq-coupled receptors and calmodulin (see Discussion). ECM: extracellular matrix, MS: mechanosensitive, Ca<sub>v</sub>: voltage-gated Ca<sup>2+</sup> channel, ΔV<sub>m</sub>: membrane depolarisation, CaM: calmodulin.</p></caption><graphic mime-subtype="tiff" mimetype="image" xlink:href="elife-66582-fig6-v1.tif"/></fig><p>Previous studies reported that the TRPM4 current contributes to the mammalian atrial action potential (<xref ref-type="bibr" rid="bib56">Simard et al., 2013</xref>) as well as to the notch and early repolarisation phases of the action potential in Purkinje cells (<xref ref-type="bibr" rid="bib25">Hof et al., 2016</xref>), providing a potential link to cardiac arrhythmias (<xref ref-type="bibr" rid="bib23">Guinamard et al., 2015</xref>; <xref ref-type="bibr" rid="bib24">Hedon et al., 2021</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2018</xref>). Importantly, there is evidence that the TRPM4 channel is a critical modulator of ventricular remodelling in cardiac hypertrophy and heart failure (<xref ref-type="bibr" rid="bib16">Frede et al., 2020</xref>; <xref ref-type="bibr" rid="bib26">Jacobs et al., 2015</xref>; <xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>; <xref ref-type="bibr" rid="bib39">Mathar et al., 2014</xref>). <xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref> reported that TRPM4 activation suppresses angiotensin II-induced cardiac hypertrophy, which is dependent on the activation of the calcineurin-NFAT pathway. It has been proposed that this is due to the Ca<sup>2+</sup>-dependent modulation of TRPM4 activity, which leads to membrane depolarisation in cardiomyocytes and thus reduces the driving force for Ca<sup>2+</sup> influx via store-operated calcium entry (SOCE) through TRP canonical type 1 (TRPC1) and type 3 (TRPC3) ion channels (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>; <xref ref-type="bibr" rid="bib68">Wu et al., 2004</xref>).</p><p>To our knowledge, however, a role for TRPM4 in the LVH induced by mechanical pressure overload has not been demonstrated previously. We propose here that a mechanical stimulus, such as that exerted by TAC, is converted to downstream Ca<sup>2+</sup> signalling via the activity of mechanosensitive ion channels in the plasma membrane. Although the mechanosensitivity of TRP-type ion channels is still the subject of debate (<xref ref-type="bibr" rid="bib10">Cox et al., 2019</xref>; <xref ref-type="bibr" rid="bib19">Gottlieb et al., 2008</xref>), mammalian TRP ion channels, including TRPM4, have recently been shown to be insensitive to membrane stretch (<xref ref-type="bibr" rid="bib8">Constantine et al., 2016</xref>; <xref ref-type="bibr" rid="bib47">Nikolaev et al., 2019</xref>). Therefore, TRPM4 does not appear to be the primary mechanosensor responding to pressure overload. It is more likely to be a secondary ionotropic receptor downstream of a Ca<sup>2+</sup>-permeable mechanosensitive ion channel, such as Piezo1 (<xref ref-type="bibr" rid="bib18">Gnanasambandam et al., 2015</xref>; <xref ref-type="bibr" rid="bib58">Syeda et al., 2016</xref>) or TRPV2/4 (<xref ref-type="bibr" rid="bib34">Lieben and Carmeliet, 2012</xref>), that functions as the primary mechanoreceptor responding directly to pressure overload and thus initiating the hypertrophic response in TAC, which is not dependent on activation of the calcineurin-NFAT pathway (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>).</p><p>Stimulated by the local Ca<sup>2+</sup> influx through a Ca<sup>2+</sup>-permeable mechanosensitive ion channel, the Na<sup>+</sup>-permeable TRPM4 activity then could either induce reverse activity of the Na<sup>+</sup>/ Ca<sup>2+ </sup>exchanger through local Na<sup>+</sup> loading (<xref ref-type="bibr" rid="bib9">Conway and Koushik, 2001</xref>; <xref ref-type="bibr" rid="bib62">Wang et al., 2018</xref>) or depolarise the cardiomyocyte cell membrane to stimulate voltage-gated Ca<sup>2+</sup> channels. Such potential downstream ion channels include the L-type Ca<sup>2+</sup> channels, which were reported to mediate hypertrophic cardiomyopathy (<xref ref-type="bibr" rid="bib61">Viola and Hool, 2017</xref>), as well as the T-type Ca<sup>2+</sup> channels whose splice variants were found to be regulated in rat LV hypertrophic hearts induced by aortic constriction (<xref ref-type="bibr" rid="bib11">Cribbs, 2010</xref>). Either of these outcomes would lead to a high-amplitude increase in local Ca<sup>2+</sup>. Thus, as a Ca<sup>2+</sup>-dependent non-selective monovalent cation channel (<xref ref-type="bibr" rid="bib8">Constantine et al., 2016</xref>; <xref ref-type="bibr" rid="bib32">Launay et al., 2002</xref>; <xref ref-type="bibr" rid="bib48">Nilius et al., 2003</xref>; <xref ref-type="bibr" rid="bib49">Nilius et al., 2005</xref>), TRPM4 could contribute to TAC-induced LVH by modulating downstream voltage-gated Ca<sup>2+</sup> ion channels or the Na<sup>+</sup>/Ca<sup>2+</sup> exchanger (<xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>In this study, we confirmed the involvement of TRPM4 in TAC-induced LVH using <italic>Trpm4</italic> cKO mice. Despite identical TAC-induced increases in haemodynamic load in both WT and <italic>Trpm4</italic> cKO mice, the latter displayed a significantly reduced LVH response. This is in contrast to the increased hypertrophy reported in angiotensin II-treated <italic>Trpm4</italic> cKO mice that is mediated by the calcineurin-NFAT pathway (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>). These differential effects of TRPM4 on angiotensin II-mediated (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>) and TAC-induced LVH support our previous finding that these two hypertrophic stimuli are mediated by distinct signalling mechanisms. Thus, in agreement with the present findings, we showed previously that the CaMKII-HDAC4-MEF2 pathway, but not the calcineurin-NFAT signalling pathway, is activated in response to TAC-induced pressure overload (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>). This is most likely because CaMKIIδ and calcineurin respond to different characteristics of intracellular Ca<sup>2+</sup> signalling (<xref ref-type="bibr" rid="bib12">De Koninck and Schulman, 1998</xref>; <xref ref-type="bibr" rid="bib13">Dolmetsch et al., 1997</xref>). Whereas calcineurin activation requires a sustained increase in the resting intracellular Ca<sup>2+</sup> concentration, CaMKIIδ activation is more sensitive to high-frequency/high amplitude Ca<sup>2+</sup> oscillations (<xref ref-type="bibr" rid="bib7">Colella et al., 2008</xref>; <xref ref-type="bibr" rid="bib12">De Koninck and Schulman, 1998</xref>), which are known to occur with TAC-induced aortic constriction (<xref ref-type="bibr" rid="bib6">Chen et al., 2011</xref>). CaM responds to this high-amplitude Ca<sup>2+</sup> stimulus through the lower affinity Ca<sup>2+</sup> binding site at its N-lobe (<xref ref-type="bibr" rid="bib15">Evans and Shea, 2009</xref>; <xref ref-type="bibr" rid="bib54">Saimi and Kung, 2002</xref>), which subsequently activates CaMKIIδ and thus stimulates the CaMKII-HDAC4-MEF2 pathway (<xref ref-type="bibr" rid="bib70">Yu et al., 2021</xref>). Moreover, once activated, CaMKII has been shown to inhibit calcineurin activity (<xref ref-type="bibr" rid="bib30">Kreusser et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">MacDonnell et al., 2009</xref>; <xref ref-type="fig" rid="fig6">Figure 6</xref>).</p><p>The high-frequency/high-amplitude Ca<sup>2+ </sup>oscillations characteristic of TAC and the consequent intermittent nature of the resulting TRPM4 activation, as distinct from the persistent activation associated with angiotensin II-induced hypertrophy, may mean that TAC-induced TRPM4 activation does not reduce the driving force for Ca<sup>2+</sup> influx via SOCE that characterises the anti-hypertrophic action of TRPM4 in angiotensin II-induced hypertrophy (see above). Rather, in TAC-induced hypertrophy, TRPM4 acts as a second messenger, amplifying the small load-dependent Ca<sup>2+</sup> signal produced by a mechanosensitive Ca<sup>2+</sup>-permeable ion channel. This would account for the pro-hypertrophic effect of TRPM4 in TAC-induced hypertrophy as distinct from its anti-hypertrophic effect in angiotensin II-induced hypertrophy.</p><p>In terms of the signalling pathway mediating pressure overload-induced LVH, we found that in <italic>Trpm4</italic> cKO TAC hearts, the reduced LVH response was associated with significantly less activation of the CaMKII-HDAC4-MEF2 pathway, with reduced CaMKIIδ activation resulting in reduced nuclear export of HDAC4. Since nuclear HDAC4 inhibits MEF2A activity, a reduction in HDAC4 nuclear export would result in diminished MEF2A disinhibition and, given that MEF2A is a critical nuclear transcriptional regulator causing pathological cardiac remodelling, reduced hypertrophy development (<xref ref-type="bibr" rid="bib51">Passier et al., 2000</xref>) as, indeed, observed here in <italic>Trpm4</italic> cKO TAC hearts.</p><p>Decreased expression of TRPM4 channels in <italic>Trpm4</italic> cKO animals likely modifies Ca<sup>2+</sup>-signalling, which directly regulates CaMKIIδ activation and its downstream pathway in response to TAC. Comparable with a study reporting that blockade of MEF2 acetylation can permit recovery from pathological cardiac hypertrophy without impairing physiologic adaptation (<xref ref-type="bibr" rid="bib64">Wei et al., 2017</xref>), the lower concentration and reduced activity of MEF2A that we found in <italic>Trpm4</italic> cKO TAC hearts suggest that inhibition of TRPM4 channels is potentially a viable therapeutic option for reducing pathological hypertrophy in response to pressure overload.</p><p>Interestingly, although the calcineurin-NFAT hypertrophic signalling pathway is not activated by TAC in WT hearts, it was partially activated in <italic>Trpm4</italic> cKO TAC hearts, which manifested itself in the inhibition of GSK3β-mediated NFATc4 nuclear export and by an increase in GATA4. This may be explained by the reduction of the cytoplasmic CaMKIIδ in <italic>Trpm4</italic> cKO TAC hearts, as CaMKII negatively regulates calcineurin activity (<xref ref-type="bibr" rid="bib30">Kreusser et al., 2014</xref>; <xref ref-type="bibr" rid="bib36">MacDonnell et al., 2009</xref>; <xref ref-type="fig" rid="fig6">Figure 6</xref>). It is notable, nevertheless, that the net effect of the loss of TRPM4 was a significant reduction in TAC-induced LVH, indicating that the direct effect of less activation of the CaMKII-HDAC4-MEF2 pathway in reducing hypertrophy development outweighed the indirect pro-hypertrophic effect resulting from blunting CaMKIIδ’s inhibition of calcineurin.</p><p>In summary, our study provides compelling evidence that TRPM4 plays an important role in pressure overload-induced pathological LVH, with diminished TRPM4 expression reducing TAC-induced hypertrophy. Furthermore, we demonstrated that TRPM4 is a likely component of a cardiac mechanotransduction process that activates the CaMKII-HDAC4-MEF2 pathway in response to TAC. It is likely that TRPM4 is activated by upstream primary mechanoreceptors, such as Piezo1 or TRPV2/4 channels, which provide the first step in this mechanotransduction pathway. These findings expand our understanding of the molecular mechanism underlying mechanical pressure overload-induced LVH. Moreover, our work provides new insights into possible treatment strategies for limiting pressure overload-induced pathological hypertrophy.</p></sec><sec id="s4" sec-type="methods"><title id="head_12">Methods</title><table-wrap id="keyresource" position="anchor"><label>Key resources table</label><table frame="hsides" rules="groups"><thead><tr><th valign="top">Reagent type (species) or resource</th><th valign="top">Designation</th><th valign="top">Source or reference</th><th valign="top">Identifiers</th><th valign="top">Additional information</th></tr></thead><tbody><tr><td valign="top">Antibody</td><td valign="top">Anti-TRPM4 <break/>(rabbit polyclonal)</td><td valign="top">Alomone Labs</td><td valign="top">Cat# ACC-044, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2040250">AB_2040250</ext-link></td><td valign="top">Western blot (1:200)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-CaMKII delta <break/>(rabbit monoclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab181052, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2891241">AB_2891241</ext-link></td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-p-CaMKII (Thr287) <break/>(rabbit polyclonal)</td><td valign="top">Thermo Fisher Scientific</td><td valign="top">Cat# PA5-37833, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2554441">AB_2554441</ext-link></td><td valign="top">Western blot (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-HDAC4 <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 7628 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10860255">AB_10860255</ext-link></td><td valign="top">Western blot (1:1500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-p-HDAC4 (Ser246) <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 3443 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_2118723">AB_2118723</ext-link></td><td valign="top">Western blot (1:1500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-MEF2A <break/>(rabbit polyclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 9736 <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10691852">AB_10691852</ext-link></td><td valign="top">Western blot (1:3000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-NFATc4 <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab99431, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_10675673">AB_10675673</ext-link></td><td valign="top">Western blot (1:1500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GSK3β <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 9315, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_490890">AB_490890</ext-link></td><td valign="top">Western blot (1:500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-p-GSK3β (Ser9) <break/>(rabbit polyclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 9336, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_331405">AB_331405</ext-link></td><td valign="top">Western blot (1:1500)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GATA4 <break/>(mouse monoclonal)</td><td valign="top">Santa Cruz Biotechnology</td><td valign="top">Cat# sc-25310, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_627667">AB_627667</ext-link></td><td valign="top">Western blot (1:1000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-GAPDH <break/>(rabbit monoclonal)</td><td valign="top">Cell Signaling Technology</td><td valign="top">Cat# 2118, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_561053">AB_561053</ext-link></td><td valign="top">Western blot <break/>(1:10,000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Anti-Histone H2B <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab1790, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_302612">AB_302612</ext-link></td><td valign="top">Western blot (1:5000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Goat anti-rabbit IgG (goat polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab6721, <break/>RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_955447">AB_955447</ext-link></td><td valign="top">Western blot (1:10,000)</td></tr><tr><td valign="top">Antibody</td><td valign="top">Rabbit anti-mouse IgG <break/>(rabbit polyclonal)</td><td valign="top">Abcam</td><td valign="top">Cat# ab6728, RRID:<ext-link ext-link-type="uri" xlink:href="https://scicrunch.org/resolver/RRID:AB_955440">AB_955440</ext-link></td><td valign="top">Western blot (1:5000)</td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ANP <break/>(<italic>Nppa</italic>)_F</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">TGATAGATGAAGGCAGGAAGCCGC</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">ANP(<italic>Nppa</italic>)_R</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">AGGATTGGAGCCCAGAGTGGACTAGG</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">BNP (<italic>Nppb</italic>)_F</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">TCTCCAGAGCAATTCAAGAT</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">BNP (<italic>Nppb</italic>)_R</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">AACAACTTCAGTGCGTTACA</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">α-SA (<italic>Acta1</italic>)_F</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">GTGAGATTGTGCGCGACATC</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">α-SA (<italic>Acta1</italic>)_R</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">GGCAACGGAAACGCTCATT</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Collagen III (<italic>Col3A1</italic>)_F</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">GACAGATTCTGGTGCAGAGA</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top">Collagen III (<italic>Col3A1</italic>)_R</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">CATCAACGACATCTTCAGGAAT</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Trpm4</italic>_F</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">GAGAAGCCCACAGATGCCTATG</named-content></td></tr><tr><td valign="top">Sequence-based reagent</td><td valign="top"><italic>Trpm4</italic>_R</td><td valign="top">Sigma-Aldrich</td><td valign="top">PCR primers</td><td valign="top"><named-content content-type="sequence">AGCACCGACACCACCAAGTTTG</named-content></td></tr></tbody></table></table-wrap><sec id="s4-1"><title id="head_13">Mice</title><p>In the first part of the study, we performed experiments on 11–13 week old male C57BL/6J WT mice at the Victor Chang Cardiac Research Institute, Australia. In the second part of this study, we performed surgery on C57BL/6N WT and age- and sex-matched cardiac-specific <italic>Trpm4</italic> cKO mice in Katholieke Universiteit Leuven, Belgium. <italic>Trpm4</italic><sup>flox</sup> mice were crossbred with <italic>Myl7</italic>-Cre mice to generate the <italic>Trpm4</italic> cKO mice (<xref ref-type="bibr" rid="bib27">Kecskés et al., 2015</xref>). All animals were entered into the study in a randomised order, and the investigators were blinded to genotype. All experimental procedures were approved by the Animal Ethics Committee of Garvan/St Vincent’s (Australia) or Katholieke Universiteit Leuven (Belgium), respectively, in accordance with the guidelines of both the Australian code for the care and use of animals for scientific purposes (8th edition, National Health and Medical Research Council, AU, 2013) and the Guide for the Care and Use of Laboratory Animals (8th edition, National Research Council, USA, 2011).</p></sec><sec id="s4-2"><title id="head_14">Induction of LVH</title><p>WT and <italic>Trpm4</italic> cKO mice were subjected to TAC to induce pressure overload. Mice were anesthetised with 5% isoflurane and ventilated at 120 breaths/min (Harvard Apparatus Rodent Ventilator). The transverse aortic arch was accessed via an incision in the second intercostal space and constricted with a ligature tied around a 25-gauge needle, which was then removed. The TAC procedure was modified from a published paper (<xref ref-type="bibr" rid="bib53">Rockman et al., 1994</xref>). Sham mice underwent the same procedure but the ligature was not tied. Simultaneous direct pressure recordings (1.4 F pressure catheter, AD Instruments, P/L) from both the right carotid artery and the aorta distal to the ligature (n = 20 mice) indicated a TAC pressure gradient of 60 ± 8 mmHg with this technique. Animals were sacrificed after 2 days or 14 days.</p></sec><sec id="s4-3"><title id="head_15">Invasive haemodynamic measurements</title><p>After 14 days of sham or TAC, mice were anesthetised by inhalation of isoflurane (1.5%) and a 1.4 F micro-tip pressure catheter (Millar Instruments Inc, Houston, TX) was inserted into the left ventricle via the right carotid artery. The heart rate, systolic aortic pressure, LV systolic pressure, +dP/dt, and –dP/dt were recorded (LabChart 6 Reader, AD Instruments, P/L). Animals were sacrificed, and the heart weight (HW) and left ventricle weight (LVW) normalised to BW and to tibia length (TL) were measured as indicators of LVH.</p></sec><sec id="s4-4"><title id="head_16">Mouse LV cardiomyocytes isolation and purification</title><p>WT mice were heparinised and euthanised according to the Animal Research Act 1985 No 123 (New South Wales, Australia). Hearts were dissected and perfused through the aorta and the coronary arteries by 10 ml pH 7.2 perfusion buffer containing 135 mM NaCl, 4 mM KCl, 1 mM MgCl<sub>2</sub>, 0.33 mM NaH<sub>2</sub>PO<sub>2</sub>, 10 mM HEPES, 10 mM glucose, 10 mM 2,3-butanedione 2-monoxime (BDM), and 5 mM taurine, with a Langendorff apparatus at 37°C for 5 min. Next, 30 ml digestion buffer composed of the above solution and Collagenase B, D (dose by BW: 0.4 mg/g, Roche) and Protease Enzyme Type XIV (dose by BW: 0.07 mg/g, Sigma-Aldrich) was used to perfuse the hearts for 15 min. After the perfusion, the heart was removed from the setup and placed into a pH 7.4 transfer buffer containing 135 mM NaCl, 4 mM KCl, 1 mM MgCl<sub>2</sub>, 0.33 mM NaH<sub>2</sub>PO<sub>2</sub>, 10 mM HEPES, 5.5 mM glucose, 10 mM BDM, and 5 mg/ml BSA. Both atria and the right ventricle were discarded, and the LV muscle was torn into small pieces and gently dispensed into the transfer buffer repeatedly with a pipette to isolate cardiomyocytes. The suspension was then filtered through a 200 micro filcon cup filter (BD) and centrifuged at 20 g for 2 min. After that, the cardiomyocytes were purified by a method described in a separate paper (<xref ref-type="bibr" rid="bib46">Nicks et al., 2020</xref>). We confirmed that rod-shaped cardiomyocytes accounted for more than 85% of the total purified cardiomyocytes. The isolated cardiomyocytes were frozen immediately in liquid nitrogen and stored at −80°C for following experiments.</p></sec><sec id="s4-5"><title id="head_17">Quantitative real-time polymerase chain reaction</title><p>Gene expression was determined by quantitative RT-PCR. Total RNA was extracted and purified from LV tissue and isolated cardiomyocytes with the RNeasy Fibrous Tissue Mini Kit (QIAGEN), following the manufacturer’s protocol. RNA (500 ng) was reverse transcribed into cDNA using the SuperScript III First-Strand Synthesis SuperMix kit (Invitrogen). cDNA was subjected to PCR amplification to detect ANP (<italic>Nppa</italic>), BNP (<italic>Npp</italic>b), α-SA (<italic>Acta1</italic>), collagen III (<italic>Col3a1</italic>), and <italic>Trpm4</italic> gene expression, performed with the CFX384 Touch Real-Time PCR Detection System (Bio-Rad), PCR master mix LightCycler 480 SYBR Green I Master (Invitrogen). Samples were run in technical triplicate, and the mRNA expression levels were normalised to those of GAPDH to calculate relative gene expression using delta-delta Ct method. The mouse RT-PCR primers (Sigma-Aldrich) used are shown in (Key resources table).</p></sec><sec id="s4-6"><title id="head_18">Western blotting</title><p>For total protein extraction, LV tissue and isolated cardiomyocytes were lysed in a pH 7.4 lysis buffer containing 150 mM NaCl, 50 mM Tris–HCL, 1% Triton X-100, 1 mM sodium orthovanadate, 1 mM beta-glycerophosphate, 5 mM dithiothreitol, and MiniComplete protease inhibitors (Roche); for cytoplasmic and nuclear protein extraction, LV tissue was lysed using NE-PER nuclear and cytoplasmic extraction reagents (Pierce Biotechnology) and Protesase Inhibitor Cocktail Kit and Halt Phosphatase Inhibitor Cocktail (Pierce Biotechnology), both with a homogeniser (PRO Scientific). Protein (40 μg for each sample) was loaded on 4–20% Mini-PROTEAN TGX Gels (Bio-Rad) and separated by electrophoresis. Samples were transferred to PVDF membranes (Bio-Rad), blocked with 5% bovine serum albumin (BSA), and then labelled overnight with primary antibodies (Key resources table): anti-TRPM4 (1:200, Alomone Labs), anti-CaMKIIδ (1:1000; Abcam), anti-p-CaMKII (Thr287, 1:5000; Thermo Scientific), anti-HDAC4 (1:1500; Cell Signaling Technology), anti-p-HDAC4 (Ser246, 1:1500; Cell Signalling Technology), anti-MEF2A (1:3000; Cell Signalling Technology), anti-NFATc4 (1:1500; Abcam), anti-GSK3β (1:500; Cell Signaling Technology), anti-p-GSK3β (Ser9, 1:1500; Cell Signaling Technology), and anti-GATA4 (1:1000; Santa Cruz Biotechnology). Anti-GAPDH (1:10000; Cell Signaling Technology) and anti-Histone H2B (1:5000; Abcam) were used to standardise for loading. Horseradish peroxidase-conjugated goat anti-rabbit (1:10,000) or rabbit anti-mouse (1:5000) secondary antibodies (Abcam) (Key resources table) were used at room temperature for 1 h. Immunologic detection was accomplished using Amersham ECL Western blotting detection reagents (GE Healthcare). Protein levels were quantified by densitometry using ImageJ (NIH) software. Protein levels were normalised to relative changes in Histone H2B for the nuclear fraction and GAPDH for the cytoplasmic fraction and expressed as fold changes relative to those of control animals.</p></sec><sec id="s4-7"><title id="head_19">Histology</title><p>Masson’s trichrome stain was used to quantify fibrosis in the LV (collagen fibres stain blue). The hearts were excised from isoflurane-euthanised mice and washed with phosphate-buffered saline. Then the hearts were longitudinally cut at the frontal plane, embedded into optimal cutting temperature compound (Sakura Finetek), gradually frozen in liquid nitrogen via isopentane to avoid tissue damage. Serial sections with a thickness of 6 microns were sliced with a cryostat (Leica). The slides were then stained with a Masson’s trichrome staining kit (Sigma-Aldrich) following the manufacturer’s instructions. Images of the LV were obtained with 4–6 fields per section (<xref ref-type="bibr" rid="bib40">McMullen et al., 2004</xref>) using a brightfield microscope (Leica). Blue-stained fibrosis areas within sections were determined using colour-based thresholding (<xref ref-type="bibr" rid="bib1">Abràmoff et al., 2004</xref>) and measured with ImageJ software (NIH; <ext-link ext-link-type="uri" xlink:href="http://rsbweb.nih.gov/ij/">http://rsbweb.nih.gov/ij/</ext-link>). The percentage of total fibrosis area was calculated by taking the sum of the blue-stained areas divided by the total LV area.</p></sec><sec id="s4-8"><title id="head_20">Statistics</title><p>All experiments and analyses were blinded. Averaged data are presented as means ± standard error of the mean (SEM). The statistical analysis was performed using GraphPad Prism software, version 7.04 (GraphPad). For comparisons between two sets of data, unpaired t-test was used to determine the statistical significance. For comparisons among multiple sets of data with one factor or two factors, one-way or two-way ANOVA was used accordingly, followed by Tukey’s post-hoc test. p&lt;0.05 was considered statistically significant.</p></sec></sec></body><back><ack id="ack"><title>Acknowledgements</title><p>The authors gratefully acknowledge funding from the National Health and Medical Research Council (NHMRC) of Australia to BM and MF through a project grant (APP1108013), as well as the NHMRC of Australia for a Principal Research Fellowship (APP1135974) and NSW Cardiovascular Disease Senior Scientist Grant to BM. RV, SP, and AP are supported by the BOF Katholieke Universiteit Leuven (TRPLe) and the FWO-Vlaanderen (G0E0317N). CDC is supported by an NSW Health EMCR Fellowship. YG is supported by the Australian Government Research Training Program (RTP). This work is part of a PhD thesis of YG.</p></ack><sec id="s5" sec-type="additional-information"><title>Additional information</title><fn-group content-type="competing-interest"><title>Competing interests</title><fn fn-type="COI-statement" id="conf1"><p>No competing interests declared</p></fn></fn-group><fn-group content-type="author-contribution"><title>Author contributions</title><fn fn-type="con" id="con1"><p>Data curation, Formal analysis, Validation, Investigation, Methodology, Writing - original draft</p></fn><fn fn-type="con" id="con2"><p>Conceptualization, Data curation, Formal analysis, Supervision, Investigation, Visualization, Writing - original draft</p></fn><fn fn-type="con" id="con3"><p>Data curation, Supervision, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con4"><p>Data curation, Formal analysis, Validation, Investigation, Visualization, Methodology</p></fn><fn fn-type="con" id="con5"><p>Formal analysis, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con6"><p>Data curation, Supervision, Methodology</p></fn><fn fn-type="con" id="con7"><p>Data curation, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con8"><p>Data curation, Validation, Methodology</p></fn><fn fn-type="con" id="con9"><p>Data curation, Validation, Investigation, Methodology</p></fn><fn fn-type="con" id="con10"><p>Data curation, Investigation, Methodology</p></fn><fn fn-type="con" id="con11"><p>Conceptualization, Supervision, Investigation, Writing - original draft</p></fn><fn fn-type="con" id="con12"><p>Resources, Funding acquisition, Writing - original draft</p></fn><fn fn-type="con" id="con13"><p>Resources, Funding acquisition, Methodology, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con14"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Methodology, Writing - original draft, Project administration</p></fn><fn fn-type="con" id="con15"><p>Conceptualization, Resources, Supervision, Funding acquisition, Validation, Methodology, Writing - original draft, Project administration</p></fn></fn-group><fn-group content-type="ethics-information"><title>Ethics</title><fn fn-type="other"><p>Animal experimentation: This study was performed in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of the National Health and Medical Research Council of Australia. All of the animals were handled according to approved institutional animal care and use. The protocol was approved by the Garvan Institute of Medical Research/St Vincent's Hospital Animal Ethics Committee (Project No. 20_06). All surgery was performed under sodium pentobarbital anesthesia, and every effort was made to minimize suffering.</p></fn></fn-group></sec><sec id="s6" sec-type="supplementary-material"><title>Additional files</title><supplementary-material id="sdata1"><label>Source data 1.</label><caption><title>Western blots.</title></caption><media mime-subtype="zip" mimetype="application" xlink:href="elife-66582-data1-v1.zip"/></supplementary-material><supplementary-material id="supp1"><label>Supplementary file 1.</label><caption><title>Haemodynamic and anatomical parameters after 2 days and 14 days of sham/TAC in WT and <italic>Trpm4</italic> cKO mice.</title><p>Haemodynamic measurements include heart rate (HR), aortic systolic and diastolic pressure, LV systolic pressure, dP/dt<sub>max</sub> and dP/dt<sub>min</sub>; anatomical measurements include body weight (BW), heart weight (HW), LV weight (LVW), lung weight (LW), tibial length (TL), heart weight normalised by body weight (HW/BW), LV weight normalised by body weight and tibial length (LVW/BW; LVW/TL), lung weight normalised by body weight (LW/BW). Data are presented as means ± SEM. Comparison between sham and TAC in WT or <italic>Trpm4</italic> cKO groups: **p&lt;0.01, ***p&lt;0.001; Comparison between WT and <italic>Trpm4</italic> cKO TAC groups: <sup>#</sup>p&lt;0.05, <sup>###</sup>p&lt;0.001.</p></caption><media mime-subtype="docx" mimetype="application" xlink:href="elife-66582-supp1-v1.docx"/></supplementary-material><supplementary-material id="transrepform"><label>Transparent reporting form</label><media mime-subtype="docx" mimetype="application" xlink:href="elife-66582-transrepform-v1.docx"/></supplementary-material></sec><sec id="s7" sec-type="data-availability"><title>Data availability</title><p>All data generated or analysed during this study are included in the manuscript and supporting files. Source data files have been provided for all the figures and tables.</p></sec><ref-list><title>References</title><ref id="bib1"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Abràmoff</surname> <given-names>MD</given-names></name><name><surname>Magalhães</surname> <given-names>PJ</given-names></name><name><surname>Ram</surname> <given-names>SJ</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Image processing with ImageJ</article-title><source>Biophotonics International</source><volume>11</volume><fpage>36</fpage><lpage>42</lpage></element-citation></ref><ref id="bib2"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Adams</surname> <given-names>JW</given-names></name><name><surname>Sakata</surname> <given-names>Y</given-names></name><name><surname>Davis</surname> <given-names>MG</given-names></name><name><surname>Sah</surname> <given-names>VP</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Liggett</surname> <given-names>SB</given-names></name><name><surname>Chien</surname> <given-names>KR</given-names></name><name><surname>Brown</surname> <given-names>JH</given-names></name><name><surname>Dorn</surname> <given-names>GW</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Enhanced galphaq signaling: a common pathway mediates cardiac hypertrophy and apoptotic heart failure</article-title><source>PNAS</source><volume>95</volume><fpage>10140</fpage><lpage>10145</lpage><pub-id pub-id-type="doi">10.1073/pnas.95.17.10140</pub-id><pub-id pub-id-type="pmid">9707614</pub-id></element-citation></ref><ref id="bib3"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backs</surname> <given-names>J</given-names></name><name><surname>Song</surname> <given-names>K</given-names></name><name><surname>Bezprozvannaya</surname> <given-names>S</given-names></name><name><surname>Chang</surname> <given-names>S</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>CaM kinase II selectively signals to histone deacetylase 4 during cardiomyocyte hypertrophy</article-title><source>Journal of Clinical Investigation</source><volume>116</volume><fpage>1853</fpage><lpage>1864</lpage><pub-id pub-id-type="doi">10.1172/JCI27438</pub-id><pub-id pub-id-type="pmid">16767219</pub-id></element-citation></ref><ref id="bib4"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Backs</surname> <given-names>J</given-names></name><name><surname>Backs</surname> <given-names>T</given-names></name><name><surname>Neef</surname> <given-names>S</given-names></name><name><surname>Kreusser</surname> <given-names>MM</given-names></name><name><surname>Lehmann</surname> <given-names>LH</given-names></name><name><surname>Patrick</surname> <given-names>DM</given-names></name><name><surname>Grueter</surname> <given-names>CE</given-names></name><name><surname>Qi</surname> <given-names>X</given-names></name><name><surname>Richardson</surname> <given-names>JA</given-names></name><name><surname>Hill</surname> <given-names>JA</given-names></name><name><surname>Katus</surname> <given-names>HA</given-names></name><name><surname>Bassel-Duby</surname> <given-names>R</given-names></name><name><surname>Maier</surname> <given-names>LS</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>The Delta isoform of CaM kinase II is required for pathological cardiac hypertrophy and remodeling after pressure overload</article-title><source>PNAS</source><volume>106</volume><fpage>2342</fpage><lpage>2347</lpage><pub-id pub-id-type="doi">10.1073/pnas.0813013106</pub-id><pub-id pub-id-type="pmid">19179290</pub-id></element-citation></ref><ref id="bib5"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Bers</surname> <given-names>DM</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Calcium cycling and signaling in cardiac myocytes</article-title><source>Annual Review of Physiology</source><volume>70</volume><fpage>23</fpage><lpage>49</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.70.113006.100455</pub-id><pub-id pub-id-type="pmid">17988210</pub-id></element-citation></ref><ref id="bib6"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Nakayama</surname> <given-names>H</given-names></name><name><surname>Zhang</surname> <given-names>X</given-names></name><name><surname>Ai</surname> <given-names>X</given-names></name><name><surname>Harris</surname> <given-names>DM</given-names></name><name><surname>Tang</surname> <given-names>M</given-names></name><name><surname>Zhang</surname> <given-names>H</given-names></name><name><surname>Szeto</surname> <given-names>C</given-names></name><name><surname>Stockbower</surname> <given-names>K</given-names></name><name><surname>Berretta</surname> <given-names>RM</given-names></name><name><surname>Eckhart</surname> <given-names>AD</given-names></name><name><surname>Koch</surname> <given-names>WJ</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name><name><surname>Houser</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Calcium influx through Cav1.2 is a proximal signal for pathological cardiomyocyte hypertrophy</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>50</volume><fpage>460</fpage><lpage>470</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2010.11.012</pub-id></element-citation></ref><ref id="bib7"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Colella</surname> <given-names>M</given-names></name><name><surname>Grisan</surname> <given-names>F</given-names></name><name><surname>Robert</surname> <given-names>V</given-names></name><name><surname>Turner</surname> <given-names>JD</given-names></name><name><surname>Thomas</surname> <given-names>AP</given-names></name><name><surname>Pozzan</surname> <given-names>T</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Ca2+ oscillation frequency decoding in cardiac cell hypertrophy: role of calcineurin/NFAT as Ca2+ signal integrators</article-title><source>PNAS</source><volume>105</volume><fpage>2859</fpage><lpage>2864</lpage><pub-id pub-id-type="doi">10.1073/pnas.0712316105</pub-id><pub-id pub-id-type="pmid">18287024</pub-id></element-citation></ref><ref id="bib8"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Constantine</surname> <given-names>M</given-names></name><name><surname>Liew</surname> <given-names>CK</given-names></name><name><surname>Lo</surname> <given-names>V</given-names></name><name><surname>Macmillan</surname> <given-names>A</given-names></name><name><surname>Cranfield</surname> <given-names>CG</given-names></name><name><surname>Sunde</surname> <given-names>M</given-names></name><name><surname>Whan</surname> <given-names>R</given-names></name><name><surname>Graham</surname> <given-names>RM</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Heterologously-expressed and Liposome-reconstituted human transient receptor potential melastatin 4 channel (TRPM4) is a functional tetramer</article-title><source>Scientific Reports</source><volume>6</volume><elocation-id>19352</elocation-id><pub-id pub-id-type="doi">10.1038/srep19352</pub-id><pub-id pub-id-type="pmid">26785754</pub-id></element-citation></ref><ref id="bib9"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Conway</surname> <given-names>SJ</given-names></name><name><surname>Koushik</surname> <given-names>SV</given-names></name></person-group><year iso-8601-date="2001">2001</year><article-title>Cardiac sodium-calcium exchanger: a double-edged sword</article-title><source>Cardiovascular Research</source><volume>51</volume><fpage>194</fpage><lpage>197</lpage><pub-id pub-id-type="doi">10.1016/S0008-6363(01)00356-X</pub-id><pub-id pub-id-type="pmid">11470457</pub-id></element-citation></ref><ref id="bib10"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cox</surname> <given-names>CD</given-names></name><name><surname>Bavi</surname> <given-names>N</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Biophysical principles of Ion-Channel-Mediated mechanosensory transduction</article-title><source>Cell Reports</source><volume>29</volume><fpage>1</fpage><lpage>12</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2019.08.075</pub-id><pub-id pub-id-type="pmid">31577940</pub-id></element-citation></ref><ref id="bib11"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Cribbs</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>T-type calcium channel expression and function in the diseased heart</article-title><source>Channels</source><volume>4</volume><fpage>447</fpage><lpage>452</lpage><pub-id pub-id-type="doi">10.4161/chan.4.6.12870</pub-id><pub-id pub-id-type="pmid">21139421</pub-id></element-citation></ref><ref id="bib12"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>De Koninck</surname> <given-names>P</given-names></name><name><surname>Schulman</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>Sensitivity of CaM kinase II to the frequency of Ca2+ oscillations</article-title><source>Science</source><volume>279</volume><fpage>227</fpage><lpage>230</lpage><pub-id pub-id-type="doi">10.1126/science.279.5348.227</pub-id><pub-id pub-id-type="pmid">9422695</pub-id></element-citation></ref><ref id="bib13"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Dolmetsch</surname> <given-names>RE</given-names></name><name><surname>Lewis</surname> <given-names>RS</given-names></name><name><surname>Goodnow</surname> <given-names>CC</given-names></name><name><surname>Healy</surname> <given-names>JI</given-names></name></person-group><year iso-8601-date="1997">1997</year><article-title>Differential activation of transcription factors induced by Ca2+ response amplitude and duration</article-title><source>Nature</source><volume>386</volume><fpage>855</fpage><lpage>858</lpage><pub-id pub-id-type="doi">10.1038/386855a0</pub-id><pub-id pub-id-type="pmid">9126747</pub-id></element-citation></ref><ref id="bib14"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Eder</surname> <given-names>P</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>TRPC channels as effectors of cardiac hypertrophy</article-title><source>Circulation Research</source><volume>108</volume><fpage>265</fpage><lpage>272</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.225888</pub-id><pub-id pub-id-type="pmid">21252153</pub-id></element-citation></ref><ref id="bib15"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Evans</surname> <given-names>TI</given-names></name><name><surname>Shea</surname> <given-names>MA</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>Energetics of calmodulin domain interactions with the calmodulin binding domain of CaMKII</article-title><source>Proteins: Structure, Function, and Bioinformatics</source><volume>76</volume><fpage>47</fpage><lpage>61</lpage><pub-id pub-id-type="doi">10.1002/prot.22317</pub-id><pub-id pub-id-type="pmid">19089983</pub-id></element-citation></ref><ref id="bib16"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frede</surname> <given-names>W</given-names></name><name><surname>Medert</surname> <given-names>R</given-names></name><name><surname>Poth</surname> <given-names>T</given-names></name><name><surname>Gorenflo</surname> <given-names>M</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Uhl</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>TRPM4 modulates right ventricular remodeling under pressure load accompanied with decreased expression level</article-title><source>Journal of Cardiac Failure</source><volume>26</volume><fpage>599</fpage><lpage>609</lpage><pub-id pub-id-type="doi">10.1016/j.cardfail.2020.02.006</pub-id><pub-id pub-id-type="pmid">32147520</pub-id></element-citation></ref><ref id="bib17"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Frey</surname> <given-names>N</given-names></name><name><surname>Katus</surname> <given-names>HA</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name><name><surname>Hill</surname> <given-names>JA</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Hypertrophy of the heart: a new therapeutic target?</article-title><source>Circulation</source><volume>109</volume><fpage>1580</fpage><lpage>1589</lpage><pub-id pub-id-type="doi">10.1161/01.CIR.0000120390.68287.BB</pub-id><pub-id pub-id-type="pmid">15066961</pub-id></element-citation></ref><ref id="bib18"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gnanasambandam</surname> <given-names>R</given-names></name><name><surname>Bae</surname> <given-names>C</given-names></name><name><surname>Gottlieb</surname> <given-names>PA</given-names></name><name><surname>Sachs</surname> <given-names>F</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Ionic selectivity and permeation properties of human PIEZO1 channels</article-title><source>PLOS ONE</source><volume>10</volume><elocation-id>e0125503</elocation-id><pub-id pub-id-type="doi">10.1371/journal.pone.0125503</pub-id><pub-id pub-id-type="pmid">25955826</pub-id></element-citation></ref><ref id="bib19"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gottlieb</surname> <given-names>P</given-names></name><name><surname>Folgering</surname> <given-names>J</given-names></name><name><surname>Maroto</surname> <given-names>R</given-names></name><name><surname>Raso</surname> <given-names>A</given-names></name><name><surname>Wood</surname> <given-names>TG</given-names></name><name><surname>Kurosky</surname> <given-names>A</given-names></name><name><surname>Bowman</surname> <given-names>C</given-names></name><name><surname>Bichet</surname> <given-names>D</given-names></name><name><surname>Patel</surname> <given-names>A</given-names></name><name><surname>Sachs</surname> <given-names>F</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name><name><surname>Hamill</surname> <given-names>OP</given-names></name><name><surname>Honoré</surname> <given-names>E</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Revisiting TRPC1 and TRPC6 mechanosensitivity</article-title><source>Pflügers Archiv - European Journal of Physiology</source><volume>455</volume><fpage>1097</fpage><lpage>1103</lpage><pub-id pub-id-type="doi">10.1007/s00424-007-0359-3</pub-id><pub-id pub-id-type="pmid">17957383</pub-id></element-citation></ref><ref id="bib20"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Gueffier</surname> <given-names>M</given-names></name><name><surname>Zintz</surname> <given-names>J</given-names></name><name><surname>Lambert</surname> <given-names>K</given-names></name><name><surname>Finan</surname> <given-names>A</given-names></name><name><surname>Aimond</surname> <given-names>F</given-names></name><name><surname>Chakouri</surname> <given-names>N</given-names></name><name><surname>Hédon</surname> <given-names>C</given-names></name><name><surname>Granier</surname> <given-names>M</given-names></name><name><surname>Launay</surname> <given-names>P</given-names></name><name><surname>Thireau</surname> <given-names>J</given-names></name><name><surname>Richard</surname> <given-names>S</given-names></name><name><surname>Demion</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The TRPM4 channel is functionally important for the beneficial cardiac remodeling induced by endurance training</article-title><source>Journal of Muscle Research and Cell Motility</source><volume>38</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/s10974-017-9466-8</pub-id><pub-id pub-id-type="pmid">28224334</pub-id></element-citation></ref><ref id="bib21"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinamard</surname> <given-names>R</given-names></name><name><surname>Chatelier</surname> <given-names>A</given-names></name><name><surname>Demion</surname> <given-names>M</given-names></name><name><surname>Potreau</surname> <given-names>D</given-names></name><name><surname>Patri</surname> <given-names>S</given-names></name><name><surname>Rahmati</surname> <given-names>M</given-names></name><name><surname>Bois</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Functional characterization of a ca(2+)-activated non-selective cation channel in human atrial cardiomyocytes</article-title><source>The Journal of Physiology</source><volume>558</volume><fpage>75</fpage><lpage>83</lpage><pub-id pub-id-type="doi">10.1113/jphysiol.2004.063974</pub-id><pub-id pub-id-type="pmid">15121803</pub-id></element-citation></ref><ref id="bib22"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinamard</surname> <given-names>R</given-names></name><name><surname>Demion</surname> <given-names>M</given-names></name><name><surname>Magaud</surname> <given-names>C</given-names></name><name><surname>Potreau</surname> <given-names>D</given-names></name><name><surname>Bois</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2006">2006</year><article-title>Functional expression of the TRPM4 cationic current in ventricular cardiomyocytes from spontaneously hypertensive rats</article-title><source>Hypertension</source><volume>48</volume><fpage>587</fpage><lpage>594</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000237864.65019.a5</pub-id><pub-id pub-id-type="pmid">16966582</pub-id></element-citation></ref><ref id="bib23"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Guinamard</surname> <given-names>R</given-names></name><name><surname>Bouvagnet</surname> <given-names>P</given-names></name><name><surname>Hof</surname> <given-names>T</given-names></name><name><surname>Liu</surname> <given-names>H</given-names></name><name><surname>Simard</surname> <given-names>C</given-names></name><name><surname>Sallé</surname> <given-names>L</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>TRPM4 in cardiac electrical activity</article-title><source>Cardiovascular research</source><volume>108</volume><fpage>21</fpage><lpage>30</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv213</pub-id><pub-id pub-id-type="pmid">26272755</pub-id></element-citation></ref><ref id="bib24"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hedon</surname> <given-names>C</given-names></name><name><surname>Lambert</surname> <given-names>K</given-names></name><name><surname>Chakouri</surname> <given-names>N</given-names></name><name><surname>Thireau</surname> <given-names>J</given-names></name><name><surname>Aimond</surname> <given-names>F</given-names></name><name><surname>Cassan</surname> <given-names>C</given-names></name><name><surname>Bideaux</surname> <given-names>P</given-names></name><name><surname>Richard</surname> <given-names>S</given-names></name><name><surname>Faucherre</surname> <given-names>A</given-names></name><name><surname>Le Guennec</surname> <given-names>JY</given-names></name><name><surname>Demion</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>New role of TRPM4 channel in the cardiac excitation-contraction coupling in response to physiological and pathological hypertrophy in mouse</article-title><source>Progress in Biophysics and Molecular Biology</source><volume>159</volume><fpage>105</fpage><lpage>117</lpage><pub-id pub-id-type="doi">10.1016/j.pbiomolbio.2020.09.006</pub-id><pub-id pub-id-type="pmid">33031824</pub-id></element-citation></ref><ref id="bib25"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Hof</surname> <given-names>T</given-names></name><name><surname>Sallé</surname> <given-names>L</given-names></name><name><surname>Coulbault</surname> <given-names>L</given-names></name><name><surname>Richer</surname> <given-names>R</given-names></name><name><surname>Alexandre</surname> <given-names>J</given-names></name><name><surname>Rouet</surname> <given-names>R</given-names></name><name><surname>Manrique</surname> <given-names>A</given-names></name><name><surname>Guinamard</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>TRPM4 non-selective cation channels influence action potentials in rabbit purkinje fibres</article-title><source>The Journal of Physiology</source><volume>594</volume><fpage>295</fpage><lpage>306</lpage><pub-id pub-id-type="doi">10.1113/JP271347</pub-id><pub-id pub-id-type="pmid">26548780</pub-id></element-citation></ref><ref id="bib26"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Jacobs</surname> <given-names>G</given-names></name><name><surname>Oosterlinck</surname> <given-names>W</given-names></name><name><surname>Dresselaers</surname> <given-names>T</given-names></name><name><surname>Geenens</surname> <given-names>R</given-names></name><name><surname>Kerselaers</surname> <given-names>S</given-names></name><name><surname>Himmelreich</surname> <given-names>U</given-names></name><name><surname>Herijgers</surname> <given-names>P</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Enhanced β-adrenergic cardiac reserve in Trpm4−/− mice with ischaemic heart failure</article-title><source>Cardiovascular Research</source><volume>105</volume><fpage>330</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1093/cvr/cvv009</pub-id></element-citation></ref><ref id="bib27"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kecskés</surname> <given-names>M</given-names></name><name><surname>Jacobs</surname> <given-names>G</given-names></name><name><surname>Kerselaers</surname> <given-names>S</given-names></name><name><surname>Syam</surname> <given-names>N</given-names></name><name><surname>Menigoz</surname> <given-names>A</given-names></name><name><surname>Vangheluwe</surname> <given-names>P</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>The ca(2+)-activated cation channel TRPM4 is a negative regulator of angiotensin II-induced cardiac hypertrophy</article-title><source>Basic Research in Cardiology</source><volume>110</volume><elocation-id>43</elocation-id><pub-id pub-id-type="doi">10.1007/s00395-015-0501-x</pub-id><pub-id pub-id-type="pmid">26043922</pub-id></element-citation></ref><ref id="bib28"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kehat</surname> <given-names>I</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>Molecular pathways underlying cardiac remodeling during pathophysiological stimulation</article-title><source>Circulation</source><volume>122</volume><fpage>2727</fpage><lpage>2735</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.110.942268</pub-id><pub-id pub-id-type="pmid">21173361</pub-id></element-citation></ref><ref id="bib29"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Keys</surname> <given-names>JR</given-names></name><name><surname>Greene</surname> <given-names>EA</given-names></name><name><surname>Koch</surname> <given-names>WJ</given-names></name><name><surname>Eckhart</surname> <given-names>AD</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Gq-coupled receptor agonists mediate cardiac hypertrophy via the vasculature</article-title><source>Hypertension</source><volume>40</volume><fpage>660</fpage><lpage>666</lpage><pub-id pub-id-type="doi">10.1161/01.HYP.0000035397.73223.CE</pub-id><pub-id pub-id-type="pmid">12411459</pub-id></element-citation></ref><ref id="bib30"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Kreusser</surname> <given-names>MM</given-names></name><name><surname>Lehmann</surname> <given-names>LH</given-names></name><name><surname>Keranov</surname> <given-names>S</given-names></name><name><surname>Hoting</surname> <given-names>M-O</given-names></name><name><surname>Oehl</surname> <given-names>U</given-names></name><name><surname>Kohlhaas</surname> <given-names>M</given-names></name><name><surname>Reil</surname> <given-names>J-C</given-names></name><name><surname>Neumann</surname> <given-names>K</given-names></name><name><surname>Schneider</surname> <given-names>MD</given-names></name><name><surname>Hill</surname> <given-names>JA</given-names></name><name><surname>Dobrev</surname> <given-names>D</given-names></name><name><surname>Maack</surname> <given-names>C</given-names></name><name><surname>Maier</surname> <given-names>LS</given-names></name><name><surname>Gröne</surname> <given-names>H-J</given-names></name><name><surname>Katus</surname> <given-names>HA</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name><name><surname>Backs</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Cardiac CaM kinase II genes δ and γ contribute to adverse remodeling but redundantly inhibit Calcineurin-Induced myocardial hypertrophy</article-title><source>Circulation</source><volume>130</volume><fpage>1262</fpage><lpage>1273</lpage><pub-id pub-id-type="doi">10.1161/CIRCULATIONAHA.114.006185</pub-id></element-citation></ref><ref id="bib31"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lai</surname> <given-names>Y</given-names></name><name><surname>Nairn</surname> <given-names>AC</given-names></name><name><surname>Gorelick</surname> <given-names>F</given-names></name><name><surname>Greengard</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="1987">1987</year><article-title>Ca2+/calmodulin-dependent protein kinase II: identification of autophosphorylation sites responsible for generation of Ca2+/calmodulin-independence</article-title><source>PNAS</source><volume>84</volume><fpage>5710</fpage><lpage>5714</lpage><pub-id pub-id-type="doi">10.1073/pnas.84.16.5710</pub-id><pub-id pub-id-type="pmid">3475699</pub-id></element-citation></ref><ref id="bib32"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Launay</surname> <given-names>P</given-names></name><name><surname>Fleig</surname> <given-names>A</given-names></name><name><surname>Perraud</surname> <given-names>AL</given-names></name><name><surname>Scharenberg</surname> <given-names>AM</given-names></name><name><surname>Penner</surname> <given-names>R</given-names></name><name><surname>Kinet</surname> <given-names>JP</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>TRPM4 is a Ca2+-activated nonselective cation channel mediating cell membrane depolarization</article-title><source>Cell</source><volume>109</volume><fpage>397</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(02)00719-5</pub-id><pub-id pub-id-type="pmid">12015988</pub-id></element-citation></ref><ref id="bib33"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Levy</surname> <given-names>D</given-names></name><name><surname>Garrison</surname> <given-names>RJ</given-names></name><name><surname>Savage</surname> <given-names>DD</given-names></name><name><surname>Kannel</surname> <given-names>WB</given-names></name><name><surname>Castelli</surname> <given-names>WP</given-names></name></person-group><year iso-8601-date="1990">1990</year><article-title>Prognostic implications of echocardiographically determined left ventricular mass in the framingham heart study</article-title><source>New England Journal of Medicine</source><volume>322</volume><fpage>1561</fpage><lpage>1566</lpage><pub-id pub-id-type="doi">10.1056/NEJM199005313222203</pub-id><pub-id pub-id-type="pmid">2139921</pub-id></element-citation></ref><ref id="bib34"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Lieben</surname> <given-names>L</given-names></name><name><surname>Carmeliet</surname> <given-names>G</given-names></name></person-group><year iso-8601-date="2012">2012</year><article-title>The involvement of TRP channels in bone homeostasis</article-title><source>Frontiers in Endocrinology</source><volume>3</volume><elocation-id>99</elocation-id><pub-id pub-id-type="doi">10.3389/fendo.2012.00099</pub-id><pub-id pub-id-type="pmid">22934090</pub-id></element-citation></ref><ref id="bib35"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Luczak</surname> <given-names>ED</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Granger</surname> <given-names>JM</given-names></name><name><surname>Joiner</surname> <given-names>MA</given-names></name><name><surname>Wilson</surname> <given-names>NR</given-names></name><name><surname>Gupta</surname> <given-names>A</given-names></name><name><surname>Umapathi</surname> <given-names>P</given-names></name><name><surname>Murphy</surname> <given-names>KR</given-names></name><name><surname>Reyes Gaido</surname> <given-names>OE</given-names></name><name><surname>Sabet</surname> <given-names>A</given-names></name><name><surname>Corradini</surname> <given-names>E</given-names></name><name><surname>Tseng</surname> <given-names>WW</given-names></name><name><surname>Wang</surname> <given-names>Y</given-names></name><name><surname>Heck</surname> <given-names>AJR</given-names></name><name><surname>Wei</surname> <given-names>AC</given-names></name><name><surname>Weiss</surname> <given-names>RG</given-names></name><name><surname>Anderson</surname> <given-names>ME</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Mitochondrial CaMKII causes adverse metabolic reprogramming and dilated cardiomyopathy</article-title><source>Nature Communications</source><volume>11</volume><elocation-id>4416</elocation-id><pub-id pub-id-type="doi">10.1038/s41467-020-18165-6</pub-id><pub-id pub-id-type="pmid">32887881</pub-id></element-citation></ref><ref id="bib36"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>MacDonnell</surname> <given-names>SM</given-names></name><name><surname>Weisser-Thomas</surname> <given-names>J</given-names></name><name><surname>Kubo</surname> <given-names>H</given-names></name><name><surname>Hanscome</surname> <given-names>M</given-names></name><name><surname>Liu</surname> <given-names>Q</given-names></name><name><surname>Jaleel</surname> <given-names>N</given-names></name><name><surname>Berretta</surname> <given-names>R</given-names></name><name><surname>Chen</surname> <given-names>X</given-names></name><name><surname>Brown</surname> <given-names>JH</given-names></name><name><surname>Sabri</surname> <given-names>AK</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name><name><surname>Houser</surname> <given-names>SR</given-names></name></person-group><year iso-8601-date="2009">2009</year><article-title>CaMKII negatively regulates calcineurin-NFAT signaling in cardiac myocytes</article-title><source>Circulation Research</source><volume>105</volume><fpage>316</fpage><lpage>325</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.109.194035</pub-id><pub-id pub-id-type="pmid">19608982</pub-id></element-citation></ref><ref id="bib37"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Maillet</surname> <given-names>M</given-names></name><name><surname>van Berlo</surname> <given-names>JH</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Molecular basis of physiological heart growth: fundamental concepts and new players</article-title><source>Nature Reviews Molecular Cell Biology</source><volume>14</volume><fpage>38</fpage><lpage>48</lpage><pub-id pub-id-type="doi">10.1038/nrm3495</pub-id><pub-id pub-id-type="pmid">23258295</pub-id></element-citation></ref><ref id="bib38"><element-citation publication-type="book"><person-group person-group-type="author"><name><surname>Martinac</surname> <given-names>B</given-names></name><name><surname>Cox</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2017">2017</year><chapter-title>Mechanosensory transduction: focus on ion channels</chapter-title><source>Reference Module in Life Science. Comprehensive Biophysics</source><publisher-name>Elsevier</publisher-name><fpage>108</fpage><lpage>141</lpage><pub-id pub-id-type="doi">10.1016/B978-0-12-809633-8.08094-8</pub-id></element-citation></ref><ref id="bib39"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mathar</surname> <given-names>I</given-names></name><name><surname>Kecskes</surname> <given-names>M</given-names></name><name><surname>Van der Mieren</surname> <given-names>G</given-names></name><name><surname>Jacobs</surname> <given-names>G</given-names></name><name><surname>Camacho Londoño</surname> <given-names>JE</given-names></name><name><surname>Uhl</surname> <given-names>S</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Nilius</surname> <given-names>B</given-names></name><name><surname>Herijgers</surname> <given-names>P</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2014">2014</year><article-title>Increased β-adrenergic inotropy in ventricular myocardium from Trpm4-/- mice</article-title><source>Circulation Research</source><volume>114</volume><fpage>283</fpage><lpage>294</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.114.302835</pub-id><pub-id pub-id-type="pmid">24226423</pub-id></element-citation></ref><ref id="bib40"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>McMullen</surname> <given-names>JR</given-names></name><name><surname>Shioi</surname> <given-names>T</given-names></name><name><surname>Huang</surname> <given-names>W-Y</given-names></name><name><surname>Zhang</surname> <given-names>L</given-names></name><name><surname>Tarnavski</surname> <given-names>O</given-names></name><name><surname>Bisping</surname> <given-names>E</given-names></name><name><surname>Schinke</surname> <given-names>M</given-names></name><name><surname>Kong</surname> <given-names>S</given-names></name><name><surname>Sherwood</surname> <given-names>MC</given-names></name><name><surname>Brown</surname> <given-names>J</given-names></name><name><surname>Riggi</surname> <given-names>L</given-names></name><name><surname>Kang</surname> <given-names>PM</given-names></name><name><surname>Izumo</surname> <given-names>S</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>The Insulin-like growth factor 1 receptor induces physiological heart growth via the phosphoinositide 3-Kinase(p110α) Pathway</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>4782</fpage><lpage>4793</lpage><pub-id pub-id-type="doi">10.1074/jbc.M310405200</pub-id></element-citation></ref><ref id="bib41"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molkentin</surname> <given-names>JD</given-names></name><name><surname>Lu</surname> <given-names>JR</given-names></name><name><surname>Antos</surname> <given-names>CL</given-names></name><name><surname>Markham</surname> <given-names>B</given-names></name><name><surname>Richardson</surname> <given-names>J</given-names></name><name><surname>Robbins</surname> <given-names>J</given-names></name><name><surname>Grant</surname> <given-names>SR</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="1998">1998</year><article-title>A calcineurin-dependent transcriptional pathway for cardiac hypertrophy</article-title><source>Cell</source><volume>93</volume><fpage>215</fpage><lpage>228</lpage><pub-id pub-id-type="doi">10.1016/S0092-8674(00)81573-1</pub-id><pub-id pub-id-type="pmid">9568714</pub-id></element-citation></ref><ref id="bib42"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Calcineurin and beyond: cardiac hypertrophic signaling</article-title><source>Circulation research</source><volume>87</volume><fpage>731</fpage><lpage>738</lpage><pub-id pub-id-type="doi">10.1161/01.res.87.9.731</pub-id><pub-id pub-id-type="pmid">11055975</pub-id></element-citation></ref><ref id="bib43"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Parsing good versus bad signaling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells</article-title><source>Circulation research</source><volume>113</volume><fpage>16</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.113.301667</pub-id><pub-id pub-id-type="pmid">23788503</pub-id></element-citation></ref><ref id="bib44"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Mudd</surname> <given-names>JO</given-names></name><name><surname>Kass</surname> <given-names>DA</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>Tackling heart failure in the twenty-first century</article-title><source>Nature</source><volume>451</volume><fpage>919</fpage><lpage>928</lpage><pub-id pub-id-type="doi">10.1038/nature06798</pub-id><pub-id pub-id-type="pmid">18288181</pub-id></element-citation></ref><ref id="bib45"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nakamura</surname> <given-names>M</given-names></name><name><surname>Sadoshima</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Mechanisms of physiological and pathological cardiac hypertrophy</article-title><source>Nature Reviews Cardiology</source><volume>15</volume><fpage>387</fpage><lpage>407</lpage><pub-id pub-id-type="doi">10.1038/s41569-018-0007-y</pub-id><pub-id pub-id-type="pmid">29674714</pub-id></element-citation></ref><ref id="bib46"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nicks</surname> <given-names>AM</given-names></name><name><surname>Kesteven</surname> <given-names>SH</given-names></name><name><surname>Li</surname> <given-names>M</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Chan</surname> <given-names>AY</given-names></name><name><surname>Naqvi</surname> <given-names>N</given-names></name><name><surname>Husain</surname> <given-names>A</given-names></name><name><surname>Feneley</surname> <given-names>MP</given-names></name><name><surname>Smith</surname> <given-names>NJ</given-names></name><name><surname>Iismaa</surname> <given-names>SE</given-names></name><name><surname>Graham</surname> <given-names>RM</given-names></name></person-group><year iso-8601-date="2020">2020</year><article-title>Pressure overload by suprarenal aortic constriction in mice leads to left ventricular hypertrophy without c-Kit expression in cardiomyocytes</article-title><source>Scientific Reports</source><volume>10</volume><elocation-id>15318</elocation-id><pub-id pub-id-type="doi">10.1038/s41598-020-72273-3</pub-id><pub-id pub-id-type="pmid">32948799</pub-id></element-citation></ref><ref id="bib47"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nikolaev</surname> <given-names>YA</given-names></name><name><surname>Cox</surname> <given-names>CD</given-names></name><name><surname>Ridone</surname> <given-names>P</given-names></name><name><surname>Rohde</surname> <given-names>PR</given-names></name><name><surname>Cordero-Morales</surname> <given-names>JF</given-names></name><name><surname>Vásquez</surname> <given-names>V</given-names></name><name><surname>Laver</surname> <given-names>DR</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mammalian TRP ion channels are insensitive to membrane stretch</article-title><source>Journal of Cell Science</source><volume>275</volume><elocation-id>jcs.238360</elocation-id><pub-id pub-id-type="doi">10.1242/jcs.238360</pub-id></element-citation></ref><ref id="bib48"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilius</surname> <given-names>B</given-names></name><name><surname>Prenen</surname> <given-names>J</given-names></name><name><surname>Droogmans</surname> <given-names>G</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name><name><surname>Vennekens</surname> <given-names>R</given-names></name><name><surname>Freichel</surname> <given-names>M</given-names></name><name><surname>Wissenbach</surname> <given-names>U</given-names></name><name><surname>Flockerzi</surname> <given-names>V</given-names></name></person-group><year iso-8601-date="2003">2003</year><article-title>Voltage dependence of the Ca2+-activated cation channel TRPM4</article-title><source>Journal of Biological Chemistry</source><volume>278</volume><fpage>30813</fpage><lpage>30820</lpage><pub-id pub-id-type="doi">10.1074/jbc.M305127200</pub-id><pub-id pub-id-type="pmid">12799367</pub-id></element-citation></ref><ref id="bib49"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Nilius</surname> <given-names>B</given-names></name><name><surname>Prenen</surname> <given-names>J</given-names></name><name><surname>Tang</surname> <given-names>J</given-names></name><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Owsianik</surname> <given-names>G</given-names></name><name><surname>Janssens</surname> <given-names>A</given-names></name><name><surname>Voets</surname> <given-names>T</given-names></name><name><surname>Zhu</surname> <given-names>MX</given-names></name></person-group><year iso-8601-date="2005">2005</year><article-title>Regulation of the Ca2+ sensitivity of the nonselective cation channel TRPM4</article-title><source>Journal of Biological Chemistry</source><volume>280</volume><fpage>6423</fpage><lpage>6433</lpage><pub-id pub-id-type="doi">10.1074/jbc.M411089200</pub-id><pub-id pub-id-type="pmid">15590641</pub-id></element-citation></ref><ref id="bib50"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Paradis</surname> <given-names>P</given-names></name><name><surname>Dali-Youcef</surname> <given-names>N</given-names></name><name><surname>Paradis</surname> <given-names>FW</given-names></name><name><surname>Thibault</surname> <given-names>G</given-names></name><name><surname>Nemer</surname> <given-names>M</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>Overexpression of angiotensin II type I receptor in cardiomyocytes induces cardiac hypertrophy and remodeling</article-title><source>PNAS</source><volume>97</volume><fpage>931</fpage><lpage>936</lpage><pub-id pub-id-type="doi">10.1073/pnas.97.2.931</pub-id></element-citation></ref><ref id="bib51"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Passier</surname> <given-names>R</given-names></name><name><surname>Zeng</surname> <given-names>H</given-names></name><name><surname>Frey</surname> <given-names>N</given-names></name><name><surname>Naya</surname> <given-names>FJ</given-names></name><name><surname>Nicol</surname> <given-names>RL</given-names></name><name><surname>McKinsey</surname> <given-names>TA</given-names></name><name><surname>Overbeek</surname> <given-names>P</given-names></name><name><surname>Richardson</surname> <given-names>JA</given-names></name><name><surname>Grant</surname> <given-names>SR</given-names></name><name><surname>Olson</surname> <given-names>EN</given-names></name></person-group><year iso-8601-date="2000">2000</year><article-title>CaM kinase signaling induces cardiac hypertrophy and activates the MEF2 transcription factor in vivo</article-title><source>Journal of Clinical Investigation</source><volume>105</volume><fpage>1395</fpage><lpage>1406</lpage><pub-id pub-id-type="doi">10.1172/JCI8551</pub-id><pub-id pub-id-type="pmid">10811847</pub-id></element-citation></ref><ref id="bib52"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Peyronnet</surname> <given-names>R</given-names></name><name><surname>Nerbonne</surname> <given-names>JM</given-names></name><name><surname>Kohl</surname> <given-names>P</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Cardiac Mechano-Gated ion channels and arrhythmias</article-title><source>Circulation Research</source><volume>118</volume><fpage>311</fpage><lpage>329</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.115.305043</pub-id><pub-id pub-id-type="pmid">26838316</pub-id></element-citation></ref><ref id="bib53"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Rockman</surname> <given-names>HA</given-names></name><name><surname>Wachhorst</surname> <given-names>SP</given-names></name><name><surname>Mao</surname> <given-names>L</given-names></name><name><surname>Ross</surname> <given-names>J</given-names></name></person-group><year iso-8601-date="1994">1994</year><article-title>ANG II receptor blockade prevents ventricular hypertrophy and ANF gene expression with pressure overload in mice</article-title><source>American Journal of Physiology-Heart and Circulatory Physiology</source><volume>266</volume><fpage>H2468</fpage><lpage>H2475</lpage><pub-id pub-id-type="doi">10.1152/ajpheart.1994.266.6.H2468</pub-id></element-citation></ref><ref id="bib54"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saimi</surname> <given-names>Y</given-names></name><name><surname>Kung</surname> <given-names>C</given-names></name></person-group><year iso-8601-date="2002">2002</year><article-title>Calmodulin as an ion channel subunit</article-title><source>Annual Review of Physiology</source><volume>64</volume><fpage>289</fpage><lpage>311</lpage><pub-id pub-id-type="doi">10.1146/annurev.physiol.64.100301.111649</pub-id><pub-id pub-id-type="pmid">11826271</pub-id></element-citation></ref><ref id="bib55"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Saucerman</surname> <given-names>JJ</given-names></name><name><surname>Tan</surname> <given-names>PM</given-names></name><name><surname>Buchholz</surname> <given-names>KS</given-names></name><name><surname>McCulloch</surname> <given-names>AD</given-names></name><name><surname>Omens</surname> <given-names>JH</given-names></name></person-group><year iso-8601-date="2019">2019</year><article-title>Mechanical regulation of gene expression in cardiac myocytes and fibroblasts</article-title><source>Nature Reviews Cardiology</source><volume>16</volume><fpage>361</fpage><lpage>378</lpage><pub-id pub-id-type="doi">10.1038/s41569-019-0155-8</pub-id><pub-id pub-id-type="pmid">30683889</pub-id></element-citation></ref><ref id="bib56"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Simard</surname> <given-names>C</given-names></name><name><surname>Hof</surname> <given-names>T</given-names></name><name><surname>Keddache</surname> <given-names>Z</given-names></name><name><surname>Launay</surname> <given-names>P</given-names></name><name><surname>Guinamard</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>The TRPM4 non-selective cation channel contributes to the mammalian atrial action potential</article-title><source>Journal of Molecular and Cellular Cardiology</source><volume>59</volume><fpage>11</fpage><lpage>19</lpage><pub-id pub-id-type="doi">10.1016/j.yjmcc.2013.01.019</pub-id><pub-id pub-id-type="pmid">23416167</pub-id></element-citation></ref><ref id="bib57"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Swynghedauw</surname> <given-names>B</given-names></name></person-group><year iso-8601-date="1999">1999</year><article-title>Molecular mechanisms of myocardial remodeling</article-title><source>Physiological Reviews</source><volume>79</volume><fpage>215</fpage><lpage>262</lpage><pub-id pub-id-type="doi">10.1152/physrev.1999.79.1.215</pub-id><pub-id pub-id-type="pmid">9922372</pub-id></element-citation></ref><ref id="bib58"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Syeda</surname> <given-names>R</given-names></name><name><surname>Florendo</surname> <given-names>MN</given-names></name><name><surname>Cox</surname> <given-names>CD</given-names></name><name><surname>Kefauver</surname> <given-names>JM</given-names></name><name><surname>Santos</surname> <given-names>JS</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name><name><surname>Patapoutian</surname> <given-names>A</given-names></name></person-group><year iso-8601-date="2016">2016</year><article-title>Piezo1 channels are inherently mechanosensitive</article-title><source>Cell Reports</source><volume>17</volume><fpage>1739</fpage><lpage>1746</lpage><pub-id pub-id-type="doi">10.1016/j.celrep.2016.10.033</pub-id><pub-id pub-id-type="pmid">27829145</pub-id></element-citation></ref><ref id="bib59"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Tham</surname> <given-names>YK</given-names></name><name><surname>Bernardo</surname> <given-names>BC</given-names></name><name><surname>Ooi</surname> <given-names>JY</given-names></name><name><surname>Weeks</surname> <given-names>KL</given-names></name><name><surname>McMullen</surname> <given-names>JR</given-names></name></person-group><year iso-8601-date="2015">2015</year><article-title>Pathophysiology of cardiac hypertrophy and heart failure: signaling pathways and novel therapeutic targets</article-title><source>Archives of Toxicology</source><volume>89</volume><fpage>1401</fpage><lpage>1438</lpage><pub-id pub-id-type="doi">10.1007/s00204-015-1477-x</pub-id><pub-id pub-id-type="pmid">25708889</pub-id></element-citation></ref><ref id="bib60"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>van Berlo</surname> <given-names>JH</given-names></name><name><surname>Maillet</surname> <given-names>M</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2013">2013</year><article-title>Signaling effectors underlying pathologic growth and remodeling of the heart</article-title><source>Journal of Clinical Investigation</source><volume>123</volume><fpage>37</fpage><lpage>45</lpage><pub-id pub-id-type="doi">10.1172/JCI62839</pub-id><pub-id pub-id-type="pmid">23281408</pub-id></element-citation></ref><ref id="bib61"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Viola</surname> <given-names>HM</given-names></name><name><surname>Hool</surname> <given-names>LC</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>The L-type Ca<sup>2+</sup> channel: a mediator of hypertrophic cardiomyopathy</article-title><source>Channels</source><volume>11</volume><fpage>5</fpage><lpage>7</lpage><pub-id pub-id-type="doi">10.1080/19336950.2016.1213053</pub-id><pub-id pub-id-type="pmid">27437722</pub-id></element-citation></ref><ref id="bib62"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wang</surname> <given-names>C</given-names></name><name><surname>Naruse</surname> <given-names>K</given-names></name><name><surname>Takahashi</surname> <given-names>K</given-names></name></person-group><year iso-8601-date="2018">2018</year><article-title>Role of the TRPM4 channel in cardiovascular physiology and pathophysiology</article-title><source>Cells</source><volume>7</volume><elocation-id>62</elocation-id><pub-id pub-id-type="doi">10.3390/cells7060062</pub-id></element-citation></ref><ref id="bib63"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Watanabe</surname> <given-names>H</given-names></name><name><surname>Murakami</surname> <given-names>M</given-names></name><name><surname>Ohba</surname> <given-names>T</given-names></name><name><surname>Takahashi</surname> <given-names>Y</given-names></name><name><surname>Ito</surname> <given-names>H</given-names></name></person-group><year iso-8601-date="2008">2008</year><article-title>TRP channel and cardiovascular disease</article-title><source>Pharmacology &amp; Therapeutics</source><volume>118</volume><fpage>337</fpage><lpage>351</lpage><pub-id pub-id-type="doi">10.1016/j.pharmthera.2008.03.008</pub-id><pub-id pub-id-type="pmid">18508125</pub-id></element-citation></ref><ref id="bib64"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wei</surname> <given-names>J</given-names></name><name><surname>Joshi</surname> <given-names>S</given-names></name><name><surname>Speransky</surname> <given-names>S</given-names></name><name><surname>Crowley</surname> <given-names>C</given-names></name><name><surname>Jayathilaka</surname> <given-names>N</given-names></name><name><surname>Lei</surname> <given-names>X</given-names></name><name><surname>Wu</surname> <given-names>Y</given-names></name><name><surname>Gai</surname> <given-names>D</given-names></name><name><surname>Jain</surname> <given-names>S</given-names></name><name><surname>Hoosien</surname> <given-names>M</given-names></name><name><surname>Gao</surname> <given-names>Y</given-names></name><name><surname>Chen</surname> <given-names>L</given-names></name><name><surname>Bishopric</surname> <given-names>NH</given-names></name></person-group><year iso-8601-date="2017">2017</year><article-title>Reversal of pathological cardiac hypertrophy via the MEF2-coregulator interface</article-title><source>JCI Insight</source><volume>2</volume><elocation-id>91068</elocation-id><pub-id pub-id-type="doi">10.1172/jci.insight.91068</pub-id><pub-id pub-id-type="pmid">28878124</pub-id></element-citation></ref><ref id="bib65"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilde</surname> <given-names>AA</given-names></name><name><surname>Brugada</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Phenotypical manifestations of mutations in the genes encoding subunits of the cardiac sodium channel</article-title><source>Circulation Research</source><volume>108</volume><fpage>884</fpage><lpage>897</lpage><pub-id pub-id-type="doi">10.1161/CIRCRESAHA.110.238469</pub-id><pub-id pub-id-type="pmid">21454796</pub-id></element-citation></ref><ref id="bib66"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname> <given-names>BJ</given-names></name><name><surname>Dai</surname> <given-names>YS</given-names></name><name><surname>Bueno</surname> <given-names>OF</given-names></name><name><surname>Parsons</surname> <given-names>SA</given-names></name><name><surname>Xu</surname> <given-names>J</given-names></name><name><surname>Plank</surname> <given-names>DM</given-names></name><name><surname>Jones</surname> <given-names>F</given-names></name><name><surname>Kimball</surname> <given-names>TR</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Calcineurin/NFAT coupling participates in Pathological, but not physiological, cardiac hypertrophy</article-title><source>Circulation Research</source><volume>94</volume><fpage>110</fpage><lpage>118</lpage><pub-id pub-id-type="doi">10.1161/01.RES.0000109415.17511.18</pub-id><pub-id pub-id-type="pmid">14656927</pub-id></element-citation></ref><ref id="bib67"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wilkins</surname> <given-names>BJ</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Calcium-calcineurin signaling in the regulation of cardiac hypertrophy</article-title><source>Biochemical and Biophysical Research Communications</source><volume>322</volume><fpage>1178</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1016/j.bbrc.2004.07.121</pub-id><pub-id pub-id-type="pmid">15336966</pub-id></element-citation></ref><ref id="bib68"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Zagranichnaya</surname> <given-names>TK</given-names></name><name><surname>Gurda</surname> <given-names>GT</given-names></name><name><surname>Eves</surname> <given-names>EM</given-names></name><name><surname>Villereal</surname> <given-names>ML</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>A TRPC1/TRPC3-mediated increase in store-operated calcium entry is required for differentiation of H19-7 hippocampal neuronal cells</article-title><source>Journal of Biological Chemistry</source><volume>279</volume><fpage>43392</fpage><lpage>43402</lpage><pub-id pub-id-type="doi">10.1074/jbc.M408959200</pub-id><pub-id pub-id-type="pmid">15297455</pub-id></element-citation></ref><ref id="bib69"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Wu</surname> <given-names>X</given-names></name><name><surname>Eder</surname> <given-names>P</given-names></name><name><surname>Chang</surname> <given-names>B</given-names></name><name><surname>Molkentin</surname> <given-names>JD</given-names></name></person-group><year iso-8601-date="2010">2010</year><article-title>TRPC channels are necessary mediators of pathologic cardiac hypertrophy</article-title><source>PNAS</source><volume>107</volume><fpage>7000</fpage><lpage>7005</lpage><pub-id pub-id-type="doi">10.1073/pnas.1001825107</pub-id><pub-id pub-id-type="pmid">20351294</pub-id></element-citation></ref><ref id="bib70"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Yu</surname> <given-names>ZY</given-names></name><name><surname>Gong</surname> <given-names>H</given-names></name><name><surname>Wu</surname> <given-names>J</given-names></name><name><surname>Dai</surname> <given-names>Y</given-names></name><name><surname>Kesteven</surname> <given-names>SH</given-names></name><name><surname>Fatkin</surname> <given-names>D</given-names></name><name><surname>Martinac</surname> <given-names>B</given-names></name><name><surname>Graham</surname> <given-names>RM</given-names></name><name><surname>Feneley</surname> <given-names>MP</given-names></name></person-group><year iso-8601-date="2021">2021</year><article-title>Cardiac Gq receptors and calcineurin activation are not required for the hypertrophic response to mechanical left ventricular pressure overload</article-title><source>Frontiers in Cell and Developmental Biology</source><volume>9</volume><elocation-id>639509</elocation-id><pub-id pub-id-type="doi">10.3389/fcell.2021.639509</pub-id><pub-id pub-id-type="pmid">33659256</pub-id></element-citation></ref><ref id="bib71"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zarain-Herzberg</surname> <given-names>A</given-names></name><name><surname>Fragoso-Medina</surname> <given-names>J</given-names></name><name><surname>Estrada-Avilés</surname> <given-names>R</given-names></name></person-group><year iso-8601-date="2011">2011</year><article-title>Calcium-regulated transcriptional pathways in the normal and pathologic heart</article-title><source>IUBMB Life</source><volume>63</volume><fpage>847</fpage><lpage>855</lpage><pub-id pub-id-type="doi">10.1002/iub.545</pub-id><pub-id pub-id-type="pmid">21901815</pub-id></element-citation></ref><ref id="bib72"><element-citation publication-type="journal"><person-group person-group-type="author"><name><surname>Zou</surname> <given-names>Y</given-names></name><name><surname>Akazawa</surname> <given-names>H</given-names></name><name><surname>Qin</surname> <given-names>Y</given-names></name><name><surname>Sano</surname> <given-names>M</given-names></name><name><surname>Takano</surname> <given-names>H</given-names></name><name><surname>Minamino</surname> <given-names>T</given-names></name><name><surname>Makita</surname> <given-names>N</given-names></name><name><surname>Iwanaga</surname> <given-names>K</given-names></name><name><surname>Zhu</surname> <given-names>W</given-names></name><name><surname>Kudoh</surname> <given-names>S</given-names></name><name><surname>Toko</surname> <given-names>H</given-names></name><name><surname>Tamura</surname> <given-names>K</given-names></name><name><surname>Kihara</surname> <given-names>M</given-names></name><name><surname>Nagai</surname> <given-names>T</given-names></name><name><surname>Fukamizu</surname> <given-names>A</given-names></name><name><surname>Umemura</surname> <given-names>S</given-names></name><name><surname>Iiri</surname> <given-names>T</given-names></name><name><surname>Fujita</surname> <given-names>T</given-names></name><name><surname>Komuro</surname> <given-names>I</given-names></name></person-group><year iso-8601-date="2004">2004</year><article-title>Mechanical stress activates angiotensin II type 1 receptor without the involvement of angiotensin II</article-title><source>Nature Cell Biology</source><volume>6</volume><fpage>499</fpage><lpage>506</lpage><pub-id pub-id-type="doi">10.1038/ncb1137</pub-id></element-citation></ref></ref-list></back><sub-article article-type="decision-letter" id="sa1"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66582.sa1</article-id><title-group><article-title>Decision letter</article-title></title-group><contrib-group><contrib contrib-type="editor"><name><surname>Emoto</surname><given-names>Noriaki</given-names></name><role>Reviewing Editor</role><aff><institution>Kobe Pharmaceutical University</institution><country>Japan</country></aff></contrib></contrib-group><contrib-group><contrib contrib-type="reviewer"><name><surname>Takahashi</surname><given-names>Ken</given-names> </name><role>Reviewer</role><aff><institution>Okayama University</institution><country>Japan</country></aff></contrib><contrib contrib-type="reviewer"><name><surname>Blanton</surname><given-names>Robert</given-names> </name><role>Reviewer</role><aff><institution>Tufts Medical Center</institution><country>United States</country></aff></contrib></contrib-group></front-stub><body><boxed-text><p>Our editorial process produces two outputs: i) <ext-link ext-link-type="uri" xlink:href="https://sciety.org/articles/activity/10.1101/2020.12.21.423727">public reviews</ext-link> designed to be posted alongside <ext-link ext-link-type="uri" xlink:href="https://www.biorxiv.org/content/10.1101/2020.12.21.423727v1">the preprint</ext-link> for the benefit of readers; ii) feedback on the manuscript for the authors, including requests for revisions, shown below. We also include an acceptance summary that explains what the editors found interesting or important about the work.</p></boxed-text><p><bold>Acceptance summary:</bold></p><p>In this work, the authors subjected mice with cardiomyocyte-specific deletion of ion channel TRPM4 to transverse aortic constriction-induced pressure overload. The study demonstrates that cell-specific loss of TRPM4 in cardiomyocytes protects against pathological left ventricular hypertrophy which is associated with an attenuation of pathological changes, including the expression of genes that become dysregulated during the development of pathological hypertrophy. These findings highlight the importance of tissue-specific changes in the pathogenesis of pressure-induced LVH which will further the understanding of heart disease and pathophysiology in the context of heart failure due to arterial hypertension.</p><p><bold>Decision letter after peer review:</bold></p><p>Thank you for submitting your article &quot;The Ca<sup>2+</sup>-activated cation channel TRPM4 is a positive regulator of pressure overload-induced cardiac hypertrophy&quot; for consideration by <italic>eLife</italic>. Your article has been reviewed by 3 peer reviewers, one of whom is a member of our Board of Reviewing Editors, and the evaluation has been overseen by a Senior Editor. The following individuals involved in review of your submission have agreed to reveal their identity: Ken Takahashi (Reviewer #2); Robert Blanton (Reviewer #3).</p><p>The reviewers and Editors have discussed the reviews with one another, and this letter to help you prepare a revised submission.</p><p>Essential revisions:</p><p>This study demonstrates how the TRPM4 ion channel might act as a contributor to the mechanosensory transduction of pressure overload. Using and experimental model, the authors successfully demonstrated that cardiomyocyte-specific deletion of TRPM4 ion channel protects the left ventricle from pressure overload-induced hypertrophy. The conclusions of this paper are mostly supported by data, but some of the wording and data analysis need to be clarified and extended. Improving the following aspects would strengthen the manuscript as described below.</p><p>1. While the TRPM4 channel is well known for its association with cardiomyocyte action potential formation and arrhythmia, this manuscript only describes its role in mechanotransduction that was found in this study. The findings of this study may be more comprehensively accepted if there is a hypothesis that links the finding of this study with previous findings.</p><p>2. The authors should highlight the differences between this study and the Angiotensin II-induced cardiac hypertrophy Trpm4cKO mice model that has previously been reported (Kecskes et al., Basic Res Cardiol. 2015; 110(4): 43).</p><p>3. Signaling studies. Teasing out the effects of TRPM4 deletion on NFAT vs CaMKII signaling would be strengthened by more detailed measures of CaMKII activation state (such as phospho-specific AB to activated CaMKII); NFAT signaling (such as qPCR for RCAN); calcineurin activity or expression levels.</p><p>4. Nuclear localization studies. To improve clarity and understanding, the reviewer would prefer for authors to express all of the findings as cytoplasmic/nuclear. Further, would help to do the GAPDH and H2B blots on both the cytoplasmic and nuclear blots, to demonstrate successful fractionation of compartments.</p><p>5. Ideally, in cell culture or in vivo, it would be useful to test whether augmentation of CaMKII would restore the normal LV hypertrophy response, which would provide good evidence that CaMKII truly mediates the downstream effects of TRPM4.</p></body></sub-article><sub-article article-type="reply" id="sa2"><front-stub><article-id pub-id-type="doi">10.7554/eLife.66582.sa2</article-id><title-group><article-title>Author response</article-title></title-group></front-stub><body><disp-quote content-type="editor-comment"><p>Essential revisions:</p><p>This study demonstrates how the TRPM4 ion channel might act as a contributor to the mechanosensory transduction of pressure overload. Using an experimental model, the authors successfully demonstrated that cardiomyocyte-specific deletion of TRPM4 ion channel protects the left ventricle from pressure overload-induced hypertrophy. The conclusions of this paper are mostly supported by data, but some of the wording and data analysis need to be clarified and extended. Improving the following aspects would strengthen the manuscript as described below.</p><p>1. While the TRPM4 channel is well known for its association with cardiomyocyte action potential formation and arrhythmia, this manuscript only describes its role in mechanotransduction that was found in this study. The findings of this study may be more comprehensively accepted if there is a hypothesis that links the finding of this study with previous findings.</p></disp-quote><p>We thank the reviewer for this comment and agree that the significance of TRPM4 for cardiac electrical activity is important to mention. On p. 15, line 327-331 we now write:</p><p>“Previous studies reported that the TRPM4 current contributes to the mammalian atrial action potential (Simard, Hof, Keddache, Launay, and Guinamard, 2013) as well as to the notch and early repolarization phases of the action potential in Purkinje cells (Hof et al., 2016), providing a potential link to cardiac arrhythmias (Guinamard et al., 2015; Hedon et al., 2021; Wang et al., 2018).”</p><p>Moreover, globally speaking the influence of TRPM4 on cardiomyocyte Na<sup>+</sup> and Ca<sup>2+</sup> handling will almost certainly contribute to arrhythmia propensity as well as cardiac hypertrophy. Previous work suggests that increased TRPM4 activation may influence arrhythmias through local Na<sup>+</sup> loading and reverse mode of the N<sup>+</sup>/Ca<sup>2+</sup> exchanger (NCX) which in turn causes an increase in intracellular Ca<sup>2+</sup> (Wang et al., 2018). In fact, this mechanism could be shared in TAC-induced hypertrophy and may provide a plausible explanation for how TRPM4 activation influences Ca<sup>2+</sup> signalling to activate the CaMKII-HDAC-MEF2 pathway (Figure 6). As a result, we have included this putative link between TRPM4 and NCX activity in the Discussion as part of our hypothesis for the involvement of TRPM4 in TAC-induced LVH pathway. However, we should note that this is very distinct from the effects of TRPM4 in angiotensin II-mediated hypertrophy where channel activation is thought to reduce the driving force for store operated Ca<sup>2+</sup> entry through TRPC1 and TRPC3, as discussed at length in Major Point 2.</p><disp-quote content-type="editor-comment"><p>2. The authors should highlight the differences between this study and the Angiotensin II-induced cardiac hypertrophy Trpm4cKO mice model that has previously been reported (Kecskes et al., Basic Res Cardiol. 2015; 110(4): 43).</p></disp-quote><p>We must admit that we were slightly surprised by this comment from the reviewer because we specifically cited the Kecskes et al. (2015) <italic>Trpm4</italic> cKO study in the Introduction of our original manuscript, and we then devoted approximately half of the Discussion in our original manuscript to highlighting and explaining the differences between the Kecskes et al. (2015) <italic>Trpm4</italic> cKO study and the results of our own study. For your convenience, we have reproduced the relevant sections of our original manuscript below:</p><p>Excerpt from the Introduction: (line 111-116)</p><p>“Previous studies using <italic>Trpm4</italic> cardiomyocyte-specific knock-out (<italic>Trpm</italic>4 cKO) mice have shown that TRPM4 is a negative regulator of angiotensin II-induced cardiac hypertrophy in mice, which involves the calcineurin-NFAT pathway (Kecskes et al., 2015), and that TRPM4 is essential for survival after myocardial infarction (Hedon et al., 2021; Jacobs et al., 2015). However, whether TRPM4 plays a role in mechanical pressure overload-induced LVH has yet to be determined.”</p><p>Excerpt from the Discussion: (line 331-387)</p><p>“Importantly, there is evidence that the TRPM4 channel is a critical modulator of ventricular remodelling in cardiac hypertrophy and heart failure (Frede et al., 2020; Jacobs et al., 2015; Kecskes et al., 2015; Mathar et al., 2014). […] Moreover, once activated, CaMKII has been shown to inhibit calcineurin activity (Kreusser et al., 2014; MacDonnell et al., 2009) (Figure 6).”</p><p>Clearly, we are arguing that the role of TRPM4 in angiotensin II-induced cardiac hypertrophy is mechanistically distinct from its role in TAC-induced cardiac hypertrophy, and that this mechanistic distinction explains the inhibitory effect of TRPM4 activation on hypertrophy in the former case and the pro-hypertrophic effect of TRPM4 activation in the latter case. In the revised manuscript, we have added the following paragraph to the discussion, which provides a possible mechanism by which TRPM4 is pro-hypertrophic in response to TAC but anti-hypertrophic in response to angiotensin II: (line 388-396)</p><p>“The high-frequency/high amplitude Ca<sup>2+</sup>oscillations characteristic of TAC and the consequent intermittent nature of the resulting TRPM4 activation, as distinct from the persistent activation associated with angiotensin II-induced hypertrophy, may mean that TAC-induced TRPM4 activation does not reduce the driving force for Ca<sup>2+</sup> influx via SOCE that characterises the anti-hypertrophic action of TRPM4 in angiotensin II-induced hypertrophy (see above). Ca<sup>2+</sup>Ca<sup>2+</sup>[…] This would account for the pro-hypertrophic effect of TRPM4 in TAC-induced hypertrophy as distinct from its anti-hypertrophic effect in angiotensin II-induced hypertrophy.”</p><disp-quote content-type="editor-comment"><p>3. Signaling studies. Teasing out the effects of TRPM4 deletion on NFAT vs CaMKII signaling would be strengthened by more detailed measures of CaMKII activation state (such as phospho-specific AB to activated CaMKII); NFAT signaling (such as qPCR for RCAN); calcineurin activity or expression levels.</p></disp-quote><p>CaMKII activation status</p><p>Measuring CaMKII activation using a phospho-specific antibody was a great suggestion. We thank the reviewer for this recommendation. We have performed the new western blot experiments using a p-CaMKII antibody, specifically a marker of phosphorylation at threonine 287 which is auto-phosphorylated by CaMKII after activation and thus acts as a marker of CaMKII activation (Lai et al., 1987; Luczak et al., 2020). Briefly, we found that p-CaMKII increased in response to TAC in WT mice and this increased p-CaMKII was abolished in TAC-operated hearts from <italic>Trpm4</italic> cKO mice. Our new results are consistent with our conclusion that the CaMKII-HDAC-MEF2 pathway was activated in response to TAC-induced LV pressure overload. We have provided this data in the new Figure 4. Also, we have added these contents in both the Methods and Results sections.</p><p>Calcineurin activity</p><p>With due respect to the reviewer’s comments re calcineurin activity and NFAT signalling, the only incontrovertible evidence of calcineurin-NFAT pathway activation is direct measurement of nuclear translocation of NFAT based on measurements of the nuclear and cytoplasmic NFAT fractions, as was done in our current study – please see the review paper by Molkentin, in which he addresses this specific issue, which was cited in our original manuscript [Molkentin, J.D. (2013). Parsing good versus bad signalling pathways in the heart: role of calcineurin-nuclear factor of activated T-cells. Circ Res 113, 16-19]. On the issue of RCAN measurements, in particular, we have recently published our important finding that RCAN (MCIP1) is a particularly poor method of discriminating between calcineurin-NFAT4 pathway activation and CaMKII pathway activation: we observed similar elevations of RCAN (MCIP1) with calcineurin activation alone and with CaMKII activation in the absence of calcineurin activation (see our updated reference to Yu, ZY et al. Cardiac Gq receptors and calcineurin activation are not required for the hypertrophic response to mechanical left ventricular pressure overload. Front Cell Dev Biol. 2021 Feb 15;9:639509, originally cited as appearing in bioRxiv). As explained in our recent paper, the poor specificity of RCAN (MCIP1) is a consequence of the convergence of these two distinct signalling pathways onto a common intra-nuclear complex to initiate hypertrophic transcription and the fact that nuclear export of HDAC4 relieves the repression not only of MEF2 but also of NFAT. Derepression of both MEF2 and NFAT by CaMKII activation results in gene transcription downstream of intra-nuclear NFAT, including expression of RCAN (MCIP1). It follows that increased RCAN gene expression cannot be regarded as a specific marker of calcineurin activation. For the same reason, a similar caveat should apply to conclusions regarding calcineurin activation drawn from experiments based on the NFAT luciferase reporter. In short, we encourage the reviewer to examine our recent publication for further detail, but we are confident that our method of determining calcineurin-NFAT pathway activation and discriminating it from CaMKII pathway activation is superior to the methods suggested by the reviewer. Because we have already published these findings in detail elsewhere, we think it is sufficient to direct the reader to our previous publication (Yu et al., 2021) and the Molkentin (2013) review paper. In the Results section of the revised manuscript, therefore, we have slightly modified the text (yellow highlight) describing the absence of activation of the calcineurin-NFAT pathway after TAC, as follows: (line 286-289)</p><p>“These findings indicate that TAC did not result in increased nuclear translocation of NFATc4, the most reliable indicator of calcineurin activation (Molkentin, 2013), and confirm our previous finding (Yu et al., 2021) that the calcineurin-NFAT pathway is not activated by TAC.”</p><disp-quote content-type="editor-comment"><p>4. Nuclear localization studies. To improve clarity and understanding, the reviewer would prefer for authors to express all of the findings as cytoplasmic/nuclear. Further, would help to do the GAPDH and H2B blots on both the cytoplasmic and nuclear blots, to demonstrate successful fractionation of compartments.</p></disp-quote><p>We have seriously considered the reviewer’s suggestion to express all of our findings as cytoplasmic/nuclear ratios. We have now re-analysed our results and provided new data for cytoplasmic/nuclear ratios in Figure 4—figure supplement 2 and Figure 5—figure supplement 1, although we think that these data are not essential to support the main conclusions of our study. The cytoplasmic/nuclear ratio is of mechanistic significance only when there is a <italic>shuttle</italic> of the protein of interest between the nucleus and the cytoplasm, as is the case for HDAC4, but this is not the case for CaMKII, for example.</p><p>As requested, to confirm the purity of the fractions extracted from the LV tissue, we have performed the new estern blot experiments using the specific marker proteins: GAPDH for the cytoplasmic fraction and Histone H2B for the nuclear fraction. Each fraction was run side-by-side on the same blot and then probed separately against each of two primary antibodies: GAPDH and Histone H2B to validate the purity of each fraction. Our results demonstrated that we have successfully separated cytoplasmic and nuclear extracts with exceptionally high purity. This result has now been included in the Results section, and we have also provided the blot images in Figure 4—figure supplement 1.</p><disp-quote content-type="editor-comment"><p>5. Ideally, in cell culture or in vivo, it would be useful to test whether augmentation of CaMKII would restore the normal LV hypertrophy response, which would provide good evidence that CaMKII truly mediates the downstream effects of TRPM4.</p></disp-quote><p>We thank the reviewer for this suggestion, but we believe such an undertaking would require an extensive amount of work that would warrant a separate study. This is because in order to ‘augment’ CaMKII, we envisage two options: (1) a genetic approach (cardiomyocyte over- expression) or (2) a pharmacological approach (selective CaMKII activator).</p><p>Regarding the genetic approach, we would require a new inducible transgenic mouse model. Even if we were to attempt the same type of experiment in vitro and develop a plasmid-based approach to over-express CaMKII, in combination with electroporation or viral transduction, we have no method in vitro to mechanically stimulate adult cardiomyocytes or cardiomyocyte-like cell lines to induce hypertrophy to mimic our surgical mouse model.</p><p>Regarding the pharmacological approach, no selective CaMKII activators exist. There are CaMKII selective inhibitors such as KN-93 and this molecule even has an inactive derivate, KN-92, that can be used as a control but here we must point out that extensive studies have already documented a key role for CaMKIIδ in pressure overload induced hypertrophy using knockout mouse models. Particularly Kreusser et al., 2014 Circulation provide compelling evidence that CaMKIIδ is essential for pressure overload induced hypertrophy using a similar TAC model (see Kreusser et al., 2014 Figure 3c). This publication and others that support the role of CAMKII in TAC-induced hypertrophy are discussed at length in our previous publication: Yu et al. (2021). Frontiers in Cell and Developmental Biology.</p><p>In summary, because CaMKII is indispensable for the hypertrophic response to TAC and that nuclear export of HDAC4 is reduced in <italic>Trpm4</italic> cKO mice, we believe our data strongly supports the presented model that TRPM4 is part of the mechanosensory machinery that drives the CaMKII-HDAC4-MEF2 pathway that is selectively activated under pressure overload conditions to induce cardiac hypertrophy (Yu et al., 2021, Frontiers in Cell and Developmental Biology).</p></body></sub-article></article>